<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome - Uhlig, K - 2020 | Cochrane Library</title> <meta content="Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome - Uhlig, K - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009669.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome - Uhlig, K - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009669.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009669.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome" name="citation_title"/> <meta content="Konstantin Uhlig" name="citation_author"/> <meta content="Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Ljupcho Efremov" name="citation_author"/> <meta content="Medical School of the Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Jörn Tongers" name="citation_author"/> <meta content="University Hospital Halle (Saale)" name="citation_author_institution"/> <meta content="Stefan Frantz" name="citation_author"/> <meta content="University Hospital Würzburg" name="citation_author_institution"/> <meta content="Rafael Mikolajczyk" name="citation_author"/> <meta content="Medical School of the Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Daniel Sedding" name="citation_author"/> <meta content="University Hospital Halle (Saale)" name="citation_author_institution"/> <meta content="Julia Schumann" name="citation_author"/> <meta content="Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="julia.schumann@uk-halle.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD009669.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009669.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009669.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009669.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cardiac Output, Low [*drug therapy, etiology, mortality]; Cardiotonic Agents [*therapeutic use]; Cause of Death; Dobutamine [therapeutic use]; Enoximone [therapeutic use]; Epinephrine [therapeutic use]; Hydrazones [therapeutic use]; Myocardial Infarction [*complications, mortality]; Nitric Oxide [therapeutic use]; Placebos [therapeutic use]; Pyridazines [therapeutic use]; Randomized Controlled Trials as Topic; Shock, Cardiogenic [*drug therapy, etiology, mortality]; Simendan [therapeutic use]; Vasodilator Agents [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009669.pub4&amp;doi=10.1002/14651858.CD009669.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009669\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009669\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","th","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009669.pub4",title:"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome",firstPublishedDate:"Nov 5, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009669.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009669.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009669.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009669.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009669.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009669.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009669.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009669.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009669.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009669.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17996 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009669.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0182"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-sec-0169"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/appendices#CD009669-sec-0187"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/supinfo/CD009669StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/supinfo/CD009669StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0004">Konstantin Uhlig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0005">Ljupcho Efremov</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0006">Jörn Tongers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0007">Stefan Frantz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0008">Rafael Mikolajczyk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0009">Daniel Sedding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information#CD009669-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Julia Schumann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information/en#CD009669-sec-0200">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009669.pub4">https://doi.org/10.1002/14651858.CD009669.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009669-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009669-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009669-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009669-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009669-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009669-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD009669-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009669-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009669-abs-0001" lang="en"> <section id="CD009669-sec-0001"> <h3 class="title" id="CD009669-sec-0001">Background</h3> <p>Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) are potentially life‐threatening complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery. While there is solid evidence for the treatment of other cardiovascular diseases of acute onset, treatment strategies in haemodynamic instability due to CS and LCOS remains less robustly supported by the given scientific literature. Therefore, we have analysed the current body of evidence for the treatment of CS or LCOS with inotropic and/or vasodilating agents. This is the second update of a Cochrane review originally published in 2014. </p> </section> <section id="CD009669-sec-0002"> <h3 class="title" id="CD009669-sec-0002">Objectives</h3> <p>Assessment of efficacy and safety of cardiac care with positive inotropic agents and vasodilator agents in CS or LCOS due to AMI, HF or after cardiac surgery. </p> </section> <section id="CD009669-sec-0003"> <h3 class="title" id="CD009669-sec-0003">Search methods</h3> <p>We conducted a search in CENTRAL<i>,</i> MEDLINE, Embase and CPCI‐S Web of Science in October 2019. We also searched four registers of ongoing trials and scanned reference lists and contacted experts in the field to obtain further information. No language restrictions were applied. </p> </section> <section id="CD009669-sec-0004"> <h3 class="title" id="CD009669-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) enrolling patients with AMI, HF or cardiac surgery complicated by CS or LCOS. </p> </section> <section id="CD009669-sec-0005"> <h3 class="title" id="CD009669-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures according to Cochrane standards.</p> </section> <section id="CD009669-sec-0006"> <h3 class="title" id="CD009669-sec-0006">Main results</h3> <p>We identified 19 eligible studies including 2385 individuals (mean or median age range 56 to 73 years) and three ongoing studies. We categorised studies into 11 comparisons, all against standard cardiac care and additional other drugs or placebo. These comparisons investigated the efficacy of levosimendan versus dobutamine, enoximone or placebo; enoximone versus dobutamine, piroximone or epinephrine‐nitroglycerine; epinephrine versus norepinephrine or norepinephrine‐dobutamine; dopexamine versus dopamine; milrinone versus dobutamine and dopamine‐milrinone versus dopamine‐dobutamine. </p> <p>All trials were published in peer‐reviewed journals, and analyses were done by the intention‐to‐treat (ITT) principle. Eighteen of 19 trials were small with only a few included participants. An acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements occurred in nine of 19 trials. In general, confidence in the results of analysed studies was reduced due to relevant study limitations (risk of bias), imprecision or indirectness. Domains of concern, which showed a high risk in more than 50% of included studies, encompassed performance bias (blinding of participants and personnel) and bias affecting the quality of evidence on adverse events. </p> <p>All comparisons revealed uncertainty on the effect of inotropic/vasodilating drugs on all‐cause mortality with a low to very low quality of evidence. In detail, the findings were: levosimendan versus dobutamine (short‐term mortality: RR 0.60, 95% CI 0.36 to 1.03; participants = 1701; low‐quality evidence; long‐term mortality: RR 0.84, 95% CI 0.63 to 1.13; participants = 1591; low‐quality evidence); levosimendan versus placebo (short‐term mortality: no data available; long‐term mortality: RR 0.55, 95% CI 0.16 to 1.90; participants = 55; very low‐quality evidence); levosimendan versus enoximone (short‐term mortality: RR 0.50, 0.22 to 1.14; participants = 32; very low‐quality evidence; long‐term mortality: no data available); epinephrine versus norepinephrine‐dobutamine (short‐term mortality: RR 1.25; 95% CI 0.41 to 3.77; participants = 30; very low‐quality evidence; long‐term mortality: no data available); dopexamine versus dopamine (short‐term mortality: no deaths in either intervention arm; participants = 70; very low‐quality evidence; long‐term mortality: no data available); enoximone versus dobutamine (short‐term mortality RR 0.21; 95% CI 0.01 to 4.11; participants = 27; very low‐quality evidence; long‐term mortality: no data available); epinephrine versus norepinephrine (short‐term mortality: RR 1.81, 0.89 to 3.68; participants = 57; very low‐quality evidence; long‐term mortality: no data available); and dopamine‐milrinone versus dopamine‐dobutamine (short‐term mortality: RR 1.0, 95% CI 0.34 to 2.93; participants = 20; very low‐quality evidence; long‐term mortality: no data available). No information regarding all‐cause mortality were available for the comparisons milrinone versus dobutamine, enoximone versus piroximone and enoximone versus epinephrine‐nitroglycerine. </p> </section> <section id="CD009669-sec-0007"> <h3 class="title" id="CD009669-sec-0007">Authors' conclusions</h3> <p>At present, there are no convincing data supporting any specific inotropic or vasodilating therapy to reduce mortality in haemodynamically unstable patients with CS or LCOS. </p> <p>Considering the limited evidence derived from the present data due to a high risk of bias and imprecision, it should be emphasised that there is an unmet need for large‐scale, well‐designed randomised trials on this topic to close the gap between daily practice in critical care of cardiovascular patients and the available evidence. In light of the uncertainties in the field, partially due to the underlying methodological flaws in existing studies, future RCTs should be carefully designed to potentially overcome given limitations and ultimately define the role of inotropic agents and vasodilator strategies in CS and LCOS. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009669-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009669-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009669-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009669-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009669-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009669-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009669-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009669-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009669-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009669-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD009669-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009669-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009669-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009669-abs-0002" lang="en"> <h3>Inotropic and vasodilator strategies in people with cardiogenic shock or low cardiac output </h3> <p><b>Review question</b> </p> <p>We reviewed existing evidence on the treatment with different agents, which act by either increasing the ability of the heart to contract (inotropic drugs) or by expansion of the blood vessels (vasodilating drugs), regarding their effects on mortality in patients with cardiogenic shock (CS; shock due to critical reduction of cardiac pumping capacity) or low cardiac output syndrome (LCOS; reduced heart performance). </p> <p><b>Background</b> </p> <p>CS and LCOS represent life‐threatening entities. Drug therapy of CS and LCOS is based on substances that stimulate contraction of the heart. The potent agents are frequently used for rescue in acute cardiac care. However, evidence for the treatment of patients suffering from unstable blood circulation is limited especially with regard to mortality. </p> <p><b>Study characteristics</b> </p> <p>We included 19 studies with 2385 participants with CS or LCOS complicating myocardial infarction, heart failure or cardiac surgery. The follow‐up periods of the studies varied between the length of the recovery period and a period of up to 12 months. Eight studies were funded by the manufacturer of the investigated drug. In one study, the relationship to the pharmaceutical industry was not determined. </p> <p><b>Key results</b> </p> <p>We compared different strategies employing inotropic or vasodilating drugs (i.e. levosimendan, enoximone, piroximone, epinephrine, norepinephrine, dopexamine, milrinone, dopamine and dobutamine). Low‐quality evidence reflects uncertainty regarding short‐ and long‐term mortality in the comparison of levosimendan with dobutamine. Very low‐quality evidence reflects uncertainty regarding long‐term mortality in the comparison of levosimendan with placebo; no data were available for the short‐term follow‐up. Very low‐quality evidence reflects uncertainty regarding short‐term mortality in the comparison of levosimendan with enoximone, epinephrine with norepinephrine‐dobutamine, dopexamine with dopamine, enoximone with dobutamine, and dopamine‐milrinone with dopamine‐dobutamine; no data were available for the long‐term follow‐up. Very low‐quality evidence reflects uncertainty for all‐cause mortality in the short and long term when comparing epinephrine with norepinephrine. No data on all‐cause mortality were available in the comparison of milrinone with dobutamine, enoximone with piroximone and enoximone with epinephrine‐nitroglycerine. </p> <p><b>Quality of evidence</b> </p> <p>This evidence is current to October 2019. We have very little confidence in the results of the studies that we analysed (low‐ or very low‐quality evidence) due to relevant study limitations (risk of bias), imprecision or indirectness. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009669-sec-0182" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009669-sec-0182"></div> <h3 class="title" id="CD009669-sec-0183">Implications for practice</h3> <section id="CD009669-sec-0183"> <p>At present there are no robust and convincing data to support (specific) inotropic drug therapy to reduce mortality in haemodynamically unstable patients with CS or LCOS due to acute AMI, acute HF or cardiac surgery. </p> <p>In terms of haemodynamic improvements, levosimendan may be useful for haemodynamic stabilisation but there are still major concerns as to whether these improvements translate into prognostic benefits. This is particularly true in the settings when inotropes need to be combined with vasopressors. </p> <p>Given the favourable safety profile, levosimendan may be considered for therapeutic escalation ('ultima ratio'). </p> </section> <h3 class="title" id="CD009669-sec-0184">Implications for research</h3> <section id="CD009669-sec-0184"> <p>As reported above, there were essential differences in baseline parameters and coexisting therapeutic interventions among the trials. Therefore, better comparability of baseline conditions, especially with regard to haemodynamic parameters, vasopressor management (i.e. standardised protocols for titration), systemic inflammation and multi‐organ failure, is necessary aiming at better consistency. </p> <p>The 'missing link' in critically ill patients that is necessary for an understanding of macrocirculatory haemodynamics, as represented by CI and MAP, systemic inflammatory response and multi‐organ failure, might be the impairment of microcirculation in CS and LCOS. Without re‐establishing appropriate microcirculatory conditions, improved macrocirculatory parameters like cardiac output, cardiac input and MAP may not impact prognosis in CS and LCOS because consecutive multi‐organ failure will ultimately determine the clinical course and prognosis (<a href="./references#CD009669-bbs2-0040" title="Den UilCA , LagrandWK , Van der EntM , NiemanK , StruijsA , JewbaliLSD , et al. Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock. PLOS One2014;9(8):e103978.">Den Uil 2009b</a>). </p> <p>It has been hypothesised that the choice of the 'best available inotropic or vasoactive' drug might be less important than an early and stringent initiation of supportive therapies to prevent the development of CS and its downstream spiral (<a href="./references#CD009669-bbs2-0074" title="Nativi-NicolauJ , SelzmanCH , FangJC , StehlikJ . Pharmacologic therapies for acute cardiogenic shock. Current Opinion in Cardiology2014;29(3):250-7.">Nativi‐Nicolau 2014</a>). It seems imperative to follow the concept of 'early, goal‐directed therapy', as known from sepsis therapy, in CS and LCOS with early haemodynamic stabilisation within predefined timelines. Future clinical trials should therefore investigate whether following an early, goal‐directed therapeutic concept within defined timelines influences survival rates much more than searching for the 'best' catecholamine drug. Obviously the therapeutic differences with the established inotropic and vasoactive drugs seem to be marginal with regard to refractory survival rates. It may not be primarily important which pharmacological treatment strategy is used to achieve haemodynamic stabilisation rather than whether following the early, goal‐directed treatment concept a rapid improvement can be established in CS and LCOS. The comparative testing of very early mechanical support as a possible alternative to inotropics is also of interest (<a href="./references#CD009669-bbs2-0041" title="Den UilCA , Van MieghemNM , BastosMB , JewbaliLS , LenzenMJ , EngstromAE , et al. Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial. EuroIntervention2019;15(7):586-93.">Den Uil 2019</a>). </p> <p>Considering the limited evidence derived from the present body of evidence, due to a generally high risk of bias and imprecision because of few events, small number of participants and trials, it should be emphasised that there remains a great need for large‐scale, well‐designed, randomised controlled trials to precisely decipher different drug regimens in CS and LCOS in order to show significant changes in mortality or safety, independent of timelines and windows of opportunity. Obstacles for this approach are the issue of funding as well as the widespread use of inotropics in acute cardiological care, which hampers the design of adequate control groups. Ideally, however, future findings will help to close the gap between daily practice in critical cardiac care medicine and available evidence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009669-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009669-sec-0008"></div> <div class="table" id="CD009669-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cardiogenic shock or low cardiac output syndrome<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> levosimendan<br/><b>Comparison</b>: dobutamine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>dobutamine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> range 15 to 31 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(53 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> (0.36 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to cardiac surgery or HF.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> range 4 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>242 per 1000</b><br/>(181 to 325) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/>(0.63 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1591<br/>(4 studies)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to HF or AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in included studies with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met and 1 level for study limitation due to stopping trial early for benefit and methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo for cardiogenic shock or low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared with placebo for cardiogenic shock or low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock or low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> levosimendan </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause short‐term mortality:</b> 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> range 4 to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b><br/>(35 to 407) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> (0.16 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to HF or AMI.</p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in included studies with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Levosimendan compared to enoximone for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared with enoximone for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> levosimendan </p> <p><b>Comparison:</b> enoximone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause short‐term mortality:</b> 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> <p>(138 to 712)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> (0.22 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock.<br/><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met and 2 levels for study limitation due to stopping trial early for benefit and methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Epinephrine compared to norepinephrine‐dobutamine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine‐dobutamine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention</b>: epinephrine </p> <p><b>Comparison</b>: norepinephrine‐dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with norepinephrine‐dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/>(109 to 1003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> (0.41 to 3.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to HF.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm, and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Dopexamine compared to dopamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopexamine compared with dopamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> dopexamine </p> <p><b>Comparison:</b> dopamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopexamine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> time in hospital </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR not estimable<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with LCOS following elective surgery for CABG.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CABG:</b> coronary artery bypass graft surgery; <b>CI:</b> confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No in‐hospital deaths were observed in the study.<br/><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met, 1 level for publication bias due to incomplete outcome data and 1 level for study limitation due to methodological limitations from inappropriate administration of an intervention. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Milrinone compared to dobutamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Milrinone compared with dobutamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> milrinone </p> <p><b>Comparison:</b> dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with milrinone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009669-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enoximone compared to dobutamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with dobutamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> (0.01 to 4.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>very low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with LCOS after mitral valve surgery.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from a large observational study due to the small size of included studies in this population (<a href="./references#CD009669-bbs2-0090" title="SinghM , WhiteJ , HasdaiD , HodgsonPK , BergerPB , TopolEJ , et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock. Journal of the American College of Cardiology2007;50(18):1752–8.">Singh 2007</a>). </p> <p><sup>2</sup>No in‐hospital deaths were observed in the study.<br/><sup>3</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Epinephrine compared to norepinephrine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> epinephrine </p> <p><b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with norepinephrine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 28 days<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000<sup>1</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>482 per 1000</b> (237 to 979)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.81</b>  (0.89 to 3.68)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(285 to 937) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41 </b>  (0.78 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> Confidence interval; <b>CS:</b> cardiogenic shock; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to stopping trial early for benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Dopamine‐milrinone compared to dopamine‐dobutamine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopamine‐milrinone compared with dopamine‐dobutamine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> dopamine‐milrinone </p> <p><b>Comparison:</b> dopamine‐dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine‐dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine‐milrinone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> at intensive care unit </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(136 to 1172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.0</b> (0.34 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to HF.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to methodological limitations from lack of blinding and inappropriate random sequence generation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009669-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Enoximone compared to piroximone for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with piroximone for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> piroximone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with piroximone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009669-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Enoximone compared to epinephrine‐nitroglycerine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with epinephrine‐nitroglycerine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> epinephrine‐nitroglycerine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine‐nitroglycerine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009669-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009669-sec-0009"></div> <p>Cardiovascular diseases are the leading causes of morbidity, loss of disability‐adjusted life years and mortality worldwide (<a href="./references#CD009669-bbs2-0032" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics: 2019 update: a report from the American Heart Association. Circulation2019;139(10):E56-E528.">Benjamin 2019</a>). In 2013, the overall rate of death attributable to cardiovascular disease was 222.9 per 100,000 US citizens (<a href="./references#CD009669-bbs2-0073" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Executive summary: Heart disease and stroke statistics - 2016 Update: a report from the American Heart Association. Circulation2016;133(4):447-54.">Mozaffarian 2016</a>). The estimated direct and indirect annual costs for cardiovascular disease and stroke were 351 billion USD between 2014 and 2015 (<a href="./references#CD009669-bbs2-0032" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics: 2019 update: a report from the American Heart Association. Circulation2019;139(10):E56-E528.">Benjamin 2019</a>). As the population ages, the economic burden of cardiovascular diseases on the nation's healthcare system becomes even greater (<a href="./references#CD009669-bbs2-0033" title="Centers for Disease Control and Prevention. Heart Disease and Stroke Prevention. www.cdc.gov/chronicdisease/resources/publications/aag.htm (accessed 23 December 2019).">CDC 2019</a>). Data from the INTERHEART study showed that rates of cardiovascular disease have greatly increased with about 80% of the global burden in low‐income and middle‐income countries (<a href="./references#CD009669-bbs2-0098" title="YusufS , HawkenS , ÔunpuuS , DansT , AvezumA , LanasF , et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet2004;364:937-52.">Yusuf 2004</a>). </p> <p>Despite substantial progress in the cardiovascular field, acute heart failure continues to occur in a substantial number of cases. The underlying pathologies of impaired myocardial function are broad, spanning from valvular heart disease to systemic illness such as septic cardiomyopathy. These heterogeneously impair myocardial function and can rapidly cumulate into hypotension and tissue hypoperfusion via the complex cascade of the shock spiral (<a href="./references#CD009669-bbs2-0059" title="Hochman JS. Cardiogenic shock complicating acute myocardial infarction - expanding the paradigm. Circulation2003;107(24):2998–3002.">Hochman 2003</a>). </p> <p>Among many others, myocardial ischaemia is the most frequent cause of acutely impaired cardiac function (low cardiac output syndrome, LCOS) and, if clinically manifest, of haemodynamic instability (cardiogenic shock, CS). Acute myocardial infarction (AMI) is complicated by CS in approximately 5% to 10% of cases (<a href="./references#CD009669-bbs2-0042" title="ElbadawiA , ElgendyIY , MahmoudK , BarakatAF , MentiasA , MohamedAH ,  et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. Journal of the American College of Cardiology, Cardiovascular Interventions2019;12(18):1825–36.">Elbadawi 2019</a>; <a href="./references#CD009669-bbs2-0063" title="JegerRV , RadovanovicD , HunzikerPR , PfistererME , Stauffer J-C, ErneP , et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Annals of Internal Medicine2008;149(9):618-26.">Jeger 2008</a>; <a href="./references#CD009669-bbs2-0097" title="YehRW , SidneyS , ChandraM , SorelM , SelbyJV , GoAS . Population trends in the incidence and outcomes of acute myocardial infarction. New England Journal of Medicine2010;362(23):2155–65.">Yeh 2010</a>). While AMI has occurred less frequently in most recent years, the incidence of acute heart failure has remained unchanged (<a href="./references#CD009669-bbs2-0038" title="De LucaL , OlivariZ , FarinaA , GonziniL , LucciD , Di ChiaraA , et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. European Journal of Heart Failure2015;17(11):1124-32.">De Luca 2015</a>). Reflecting the ageing and multi‐morbid society in Western countries, the proportion of patients with cumulating cardiovascular risk and/or manifest coronary artery disease are continually increasing. Urgent interventional revascularisation is the gold standard in AMI, which is even more true in cases complicated by LCOS or CS. </p> <p>Despite modern therapy of acute heart failure, including rapid revascularisation if indicated, a substantial number of patients destabilises. In the case of continuing instability despite optimisation, different agents that enhance contractility (inotropes) and/or modulate afterload after the left ventricle are used to augment cardiac output and perfusion pressure, thereby stabilising patients at risk (<a href="./references#CD009669-bbs2-0077" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDE , ChungMK , De LemosJA , et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;127(4):e362–e425.">O'Gara 2013</a>; <a href="./references#CD009669-bbs2-0079" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure2016;18(8):891–975.">Ponikowski 2016</a>; <a href="./references#CD009669-bbs2-0091" title="StegPG , GreenlawN , TardifJC , TenderaM , FordI , KaabS , et al, CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. European Heart Journal2012;33(22):2831-40.">Steg 2012</a>). More recently, agents that integrate inotropic and vasodilating effects (i.e. inodilation), phosphodiesterase (PDE) inhibitors or calcium sensitisers have been established (<a href="./references#CD009669-bbs2-0080" title="ReyentovichA , BarghashMH , HochmanJS . Management of refractory cardiogenic shock. Nature Reviews Cardiology2016;13(8):481-92.">Reyentovich 2016</a>; <a href="./references#CD009669-bbs2-0093" title="ThieleH , OhmanEM , DeWaha-ThieleS , ZeymerU , DeschS . Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal2019;40(32):2671-83.">Thiele 2019</a>). </p> <section id="CD009669-sec-0010"> <h3 class="title" id="CD009669-sec-0010">Description of the condition</h3> <p>There is a continuum from LCOS to CS with uncertainty on the definite definition of a low cardiac output state. Haemodynamic criteria that are used include a reduced cardiac function (cardiac index (CI) &lt; 1.8 L/min/m<sup>2</sup> or &lt; 2.2 L/min/m<sup>2</sup> under inotropic therapy) and an elevated pulmonary capillary wedge pressure (PCWP) exceeding 15 mmHg (<a href="./references#CD009669-bbs2-0080" title="ReyentovichA , BarghashMH , HochmanJS . Management of refractory cardiogenic shock. Nature Reviews Cardiology2016;13(8):481-92.">Reyentovich 2016</a>). However, the definition in clinical trials vary (<a href="./references#CD009669-bbs2-0080" title="ReyentovichA , BarghashMH , HochmanJS . Management of refractory cardiogenic shock. Nature Reviews Cardiology2016;13(8):481-92.">Reyentovich 2016</a>). Clinically the condition presents with hypotension (systolic blood pressure &lt; 90 mmHg for at least 30 minutes or the need for supportive means to maintain a systolic blood pressure of &gt; 90 mmHg) and end‐organ hypoperfusion (such as cool extremities, urine output of less than 30 mL per hour, altered mental status or elevated serum lactate) (<a href="./references#CD009669-bbs2-0081" title="ReynoldsHR , HochmanJS . Cardiogenic shock - current concepts and improving outcomes. Circulation2008;117(5):686-97.">Reynolds 2008</a>). In CS, low system oxygen delivery is going along with low cardiac output and is complicated by multi‐organ dysfunction. CS represents an acute, life‐threatening medical condition, which needs immediate attention. </p> </section> <section id="CD009669-sec-0011"> <h3 class="title" id="CD009669-sec-0011">Description of the intervention</h3> <p>Drug therapy can be characterised according to the following effects:</p> <p> <ul id="CD009669-list-0001"> <li> <p>stimulation of myocardial contractility (inotropes)</p> </li> <li> <p>left ventricular unloading by arterial vasodilation (vasodilators)</p> </li> </ul> </p> <p>Drug therapy of CS is predominantly based on inotropic and vasoactive substances. They are administered for haemodynamic stabilisation by increasing cardiac output and, in turn, perfusion pressures and by optimising systemic vascular resistance (SVR). In early stages of LCOS, increased SVR often requires vasodilation to reduce afterload. Later stages are characterised by an escalating systemic inflammatory response syndrome and vasoplegia. At that point, only vasopressors at increasing dosages can restore the decreased SVR to maintain perfusion pressure. </p> </section> <section id="CD009669-sec-0012"> <h3 class="title" id="CD009669-sec-0012">How the intervention might work</h3> <p>The main strategy in the treatment of CS and LCOS is to re‐establish adequate macro‐ and microcirculation in order to stabilise oxygen supply at the cellular level and to modulate systemic inflammatory response to avoid functional and morphological cellular damage thereby preventing multi‐organ dysfunction and subsequent failure. Once cellular damage has become irreversible, therapeutic intervention, regardless of whether pharmacological‐ or device‐dependent, cannot impact long‐term mortality (<a href="./references#CD009669-bbs2-0037" title="De LucaG , SuryapranataH , OttervangerJP , AntmanEM . Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction - every minute of delay counts. Circulation2004;109(10):1223–5.">De Luca 2004</a>; <a href="./references#CD009669-bbs2-0042" title="ElbadawiA , ElgendyIY , MahmoudK , BarakatAF , MentiasA , MohamedAH ,  et al. Temporal trends and outcomes of mechanical complications in patients with acute myocardial infarction. Journal of the American College of Cardiology, Cardiovascular Interventions2019;12(18):1825–36.">Elbadawi 2019</a>; <a href="./references#CD009669-bbs2-0096" title="WindeckerS , BaxJJ , MyatA , StoneGW , MarberMS . Future treatment strategies in ST-segment elevation myocardial infarction. Lancet2013;382(9892):644–57.">Windecker 2013</a>). </p> <p>In order to stabilise patients with CS or LCOS, inotropes and/or vasopressors/vasodilators are used. Several drugs such as dobutamine, dopexamine, enoximone, milrinone, amrinone, levosimendan and istaroxime are used to increase cardiac contractility and to additionally reduce SVR thereby unloading the left ventricle from its afterload (<a href="./references#CD009669-bbs2-0035" title="CholleyB , LevyB , Fellahi J-L, LongroisD , AmourJ , OuattaraA , et al. Levosimendan in the light of the results of the recent randomized controlled trials. An expert opinion paper. Critical Care2019;23(385):1-8.">Cholley 2019</a>; <a href="./references#CD009669-bbs2-0061" title="HowOJ , RøsnerA , KildalAB , StenbergTA , GjessingPF , HermansenSE , et al. Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock. Translational Research2010;156(5):273-81.">How 2010</a>; <a href="./references#CD009669-bbs2-0070" title="LeopoldV , GayatE , PirracchioR , SpinarJ , ParenicaJ , TarvasmakiT , et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine2018;44(6):847-56.">Leopold 2018</a>; <a href="./references#CD009669-bbs2-0076" title="NieminenMS , BuerkeM , Cohen-SolalA , CostaS , EdesI , ErlikhA , et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. International Journal of Cardiology2016;218:150–7.">Nieminen 2016</a>; <a href="./references#CD009669-bbs2-0078" title="PietrangeloT , GiampietroL , De FilippisB , La RovereR , FulleS , AmorosoR . Effect of milrinone analogues on intracellular calcium increase in single living H9C2 cardiac cells. European Journal of Medicinal Chemistry2010;45(11):4928-33.">Pietrangelo 2010</a>; <a href="./references#CD009669-bbs2-0083" title="RognoniA , LupiA , LazzeroM , BongoAS , RognoniG . Levosimendan: from basic science to clinical trials. Recent Patents on Cardiovascular Drug Discovery2011;6(1):9-15.">Rognoni 2011</a>). </p> <p>In contrast to this mainly haemodynamic concept, there is a lack of proof in solid endpoints. Levosimendan, for example, has not proven a clear superiority to placebo in the patient populations that have been enrolled in various recent multicentre randomised controlled trials in CS (<a href="./references#CD009669-bbs2-0035" title="CholleyB , LevyB , Fellahi J-L, LongroisD , AmourJ , OuattaraA , et al. Levosimendan in the light of the results of the recent randomized controlled trials. An expert opinion paper. Critical Care2019;23(385):1-8.">Cholley 2019</a>). Since there is limited satisfying evidence for catecholamines in CS, beneficial effects on quality of life or cost become relevant (<a href="./references#CD009669-bbs2-0053" title="HarjolaVP , CostaS , SundR , YlikangasS , Siirilä-WarisK , MelinJ , et al, FINN-AKVA Study Group. The type of acute heart failure and the costs of hospitalization. International Journal of Cardiology2010;145(1):103-5.">Harjola 2010</a>; <a href="./references#CD009669-bbs2-0055" title="Healthcare Financial Management Association. National average costs by department for heart failure and shock. Healthcare Financial Management2010;64(3):122-3.">HFMA 2010</a>). However, while there is some evidence that inotropes like levosimendan might be cost‐effective in elective, high‐risk, cardiac surgery patients (<a href="./references#CD009669-bbs2-0086" title="Sanfilippo F, KnightJB , Scolletta S,  SantonocitoC ,  PastoreF ,  LoriniFL , et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Critical Care2017;21(1):252.">Sanfilippo 2017</a>), there is no comparable evidence in CS. </p> <p>It is an accepted notion to limit the use of inotropic agents activating the beta‐receptor cyclic adenosine monophosphate (cAMP) pathway to 'rescue' therapy of CS refractory to standard means such as volume replacement, diuretics and vasodilators. This approach is largely supported by observations from clinical trials suggesting that both short‐term as well as long‐term inotropic therapy can increase arrhythmias and mortality (<a href="./references#CD009669-bbs2-0034" title="ChioncelO , ParissisJ , MebazaaA , ThieleH , DeschS , BauersachsJ , et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure2020;22(8):1315-41. [DOI: 10.1002/ejhf.1922]">Chioncel 2020</a>). Overall, we assume that the potential benefits of inotropic support in CS enables haemodynamic stabilisation by enhancing myocardial function. With increasing dosages of inotropic support, potential benefits need to be weighed against an increase of myocardial oxygen consumption. This is particularly true in the case of ischaemic myocardium. These disadvantages may be seen as adverse effects of inotropic therapy. At present, there is only poor evidence for a reduction of cellular damage using inotropic drugs (<a href="./references#CD009669-bbs2-0094" title="TriposkiadisF , KarayannisG , GiamouzisG , SkoularigisJ , LouridasG , ButlerJ . The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. Journal of the American College of Cardiology2009;54(19):1747-62.">Triposkiadis 2009</a>; <a href="./references#CD009669-bbs2-0099" title="ZhengJ , MaJ , ZhangP , HuL , FanX , TangQ . Milrinone inhibits hypoxia or hydrogen dioxide-induced persistent sodium current in ventricular myocytes. European Journal of Pharmacology2009;616(1-3):206-12.">Zheng 2009</a>). Sole vasodilators, such as nitroglycerin or nitroprusside, on the other hand may only be used under guidance of haemodynamic monitoring in certain subgroups of CS (<a href="./references#CD009669-bbs2-0034" title="ChioncelO , ParissisJ , MebazaaA , ThieleH , DeschS , BauersachsJ , et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure2020;22(8):1315-41. [DOI: 10.1002/ejhf.1922]">Chioncel 2020</a>; <a href="./references#CD009669-bbs2-0079" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure2016;18(8):891–975.">Ponikowski 2016</a>) to improve left ventricular performance by unloading via vasodilation (<a href="./references#CD009669-bbs2-0039" title="Den UilCA , CaliskanK , LagrandWK , Van der EntM , JewbaliLS , Van KuijkJP , et al. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Medicine2009;35(11):1893-9.">Den Uil 2009a</a>; <a href="./references#CD009669-bbs2-0060" title="HollenbergSM . Vasodilators in acute heart failure. Heart Failure Reviews2007;12(2):143-7.">Hollenberg 2007</a>). </p> </section> <section id="CD009669-sec-0013"> <h3 class="title" id="CD009669-sec-0013">Why it is important to do this review</h3> <p>While there is a broad body of evidence for the acute treatment of many cardiovascular diseases such as acute coronary syndromes (ACS) in stable haemodynamic conditions, there is only limited evidence for treatment of unstable patients due to CS. The recent revision of the German‐Austrian S3 Guideline continues to solely guide the treatment of infarct‐related CS (<a href="./references#CD009669-bbs2-0095" title="WerdanK , RußM , BoekenU , BuerkeM , BriegelJ , Delle-KarthG , et al. Deutsch-österreichische S3 Leitlinie „Infarktbedingter kardiogener Schock - Diagnose, Monitoring und Therapie“. leitlinien.dgk.org/2020/deutsch-oesterreichische-s3-leitlinie-infarktbedingter-kardiogener-schock-diagnose-monitoring-und-therapie/ (accessed prior to 29 October 2020).">Werdan 2019</a>). Of note, these recommendations reveal the lack of evidence for recommended catecholamine therapy. Particularly in unstable CS patients who continue to come along with critical mortality, randomised clinical trials are difficult to design and conduct. Considering the frequent numbers and crucial outcomes of CS and LCOS, however, further insights will likely have major implications on acute cardiac care. </p> <p>Vasopressors are relevant to the overall topic but were excluded, as they are covered by another Cochrane Review on vasopressors in hypotensive shock (<a href="./references#CD009669-bbs2-0044" title="GamperG , HavelC , ArrichJ , LosertH , PaceNL , MüllnerM , et al. Vasopressors for hypotensive shock. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD003709. [DOI: 10.1002/14651858.CD003709.pub4]">Gamper 2016</a>). </p> <p>Most of the existing randomised trials on CS have shown improved haemodynamics without affecting outcome (<a href="./references#CD009669-bbs2-0093" title="ThieleH , OhmanEM , DeWaha-ThieleS , ZeymerU , DeschS . Management of cardiogenic shock complicating myocardial infarction: an update 2019. European Heart Journal2019;40(32):2671-83.">Thiele 2019</a>). Thus, haemodynamic status might not be a suitable surrogate marker of survival. Given that quality of life is not the relevant endpoint in the context of acute cardiac care, it is important to assess the effects of interventions on all‐cause mortality even though definitive proof may be difficult to achieve. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009669-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009669-sec-0014"></div> <p>To assess efficacy and safety of cardiac care with positive inotropic agents and vasodilator strategies in people with CS or LCOS due to AMI, HF or cardiac surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009669-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009669-sec-0015"></div> <section id="CD009669-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009669-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of parallel‐group design that evaluated efficacy and safety within a follow‐up including at least the in‐hospital period. We excluded cross‐over trials due to the investigation of all‐cause mortality as the primary outcome. Our focus was on the acute setting and, therefore, we excluded prevention trials and long‐term studies (treatment lasting one month or more). </p> </section> <section id="CD009669-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adult patients, aged 18 years and over, with acute LCOS (medium‐risk study population) or CS (high‐risk study population) with a follow‐up period that included at least hospitalisation. </p> </section> <section id="CD009669-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009669-list-0002"> <li> <p>Experimental intervention: we summarised treatments with investigational single drugs or combinations (whatever the dosage or intensity and mode, frequency, timing and duration of delivery) in one intervention group per substance. Therapeutic regimens were 'investigational' if they had been recently introduced into clinical practice or were compared to accepted therapeutic strategies, no matter whether these drugs had been investigated in regard to therapeutic efficacy or superiority. </p> </li> <li> <p>Control intervention: treatments without specific experimental single drugs or corresponding combinations or treatment options including other inotropic or vasodilative drugs. We summarised placebo or no treatment in one control group. </p> </li> </ul> </p> </section> <section id="CD009669-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Results of prespecified outcomes were collected. Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review. Where a published report did not appear to report one of these outcomes, we planned to access the trial protocol and contact the trial authors to ascertain whether the outcomes were measured but not reported. Relevant trials which measured these outcomes but did not report the data at all, or not in a usable format, were included in the review as part of the narrative. </p> <section id="CD009669-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009669-list-0003"> <li> <p>All‐cause mortality (short‐term: up to 1 month after treatment; long‐term: more than 1 month after treatment) </p> </li> </ul> </p> </section> <section id="CD009669-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009669-list-0004"> <li> <p>Major adverse cardiac events (MACE) (AMI, re‐infarction, peri‐operative infarction, cerebrovascular accidents, repeat PCI,  coronary artery bypass graft (CABG) surgery) (in hospital or ICU) </p> </li> <li> <p>Length of hospital stay</p> </li> <li> <p>Quality of life (in hospital or ICU; measured with validated scales, such as SF‐36)</p> </li> <li> <p>Haemodynamics (cardiac index, pulmonary capillary wedge pressure (PCWP), mean arterial pressure (MAP) (in hospital or ICU)) </p> </li> <li> <p>Adverse events (in hospital or ICU)</p> </li> <li> <p>Costs (in hospital or ICU)</p> </li> </ul> </p> </section> </section> </section> <section id="CD009669-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted searches in cooperation with Cochrane Heart to identify published and unpublished RCTs. </p> <section id="CD009669-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We updated our searches in the following databases on 24 October 2019:</p> <p> <ul id="CD009669-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 10 of 12, 2019); </p> </li> <li> <p>MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and MEDLINE (Ovid, 1946 to 23 October 2019); </p> </li> <li> <p>Embase Classic and Embase (Ovid, 1947 to 23 October 2019);</p> </li> <li> <p>CPCI‐S (Conference Proceedings Citation Index‐Science) Web of Science (Clarivate Analytics, 1990 to 24 October 2019). </p> </li> </ul> </p> <p>We used a combination of subject headings and text terms relating to CS, LCOS, drug therapy and comparative therapy trials to construct the search strategy for the review (<a href="./appendices#CD009669-sec-0188">Appendix 1</a>). We applied the Cochrane sensitivity‐maximising RCT search filter to MEDLINE and adaptations of it to Embase and Web of Science (<a href="./references#CD009669-bbs2-0069" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). No language restrictions were imposed. </p> <p>We also searched the following registers of ongoing and completed trials (<a href="./appendices#CD009669-sec-0188">Appendix 1</a>): </p> <p> <ul id="CD009669-list-0006"> <li> <p><a href="http://www.controlled-trials.com/" target="_blank">controlled-trials.com</a> (25 September 2019) </p> </li> <li> <p><a href="http://www.centerwatch.com/" target="_blank">centerwatch.com</a> (26 September 2019) </p> </li> <li> <p><a href="http://www.clinicaltrials.gov/" target="_blank">clinicalTrials.gov</a> (26 September 2019) </p> </li> <li> <p>The World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP) <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a> (26 September 2019) </p> </li> </ul> </p> </section> <section id="CD009669-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We contacted members of Cochrane Heart, experts in the field and manufacturers of the drugs (Carinoharm GmbH Germany, Fresenius Kabi Germany, Orion Corporation Finland, Sanofi Aventis Deutschland GmbH Germany, UCB Pharma GmbH Germany) for further information. In addition, we scanned reference lists from eligible trials and contacted the first authors to obtain further information on study design and to collect individual participant data. </p> </section> </section> <section id="CD009669-sec-0026"> <h3 class="title" id="CD009669-sec-0026">Data collection and analysis</h3> <section id="CD009669-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JS plus KU) independently screened studies identified using the search strategy described above by title, keywords and abstract. We accessed the full articles for further assessment if the information given suggested that the study: </p> <p> <ul id="CD009669-list-0007"> <li> <p>included patients with AMI, HF or cardiac surgery complicated by CS or LCOS</p> </li> <li> <p>compared</p> <ul id="CD009669-list-0008"> <li> <p>cardiac care with versus without inotropic therapies, or</p> </li> <li> <p>cardiac care with versus without therapies having vasodilator properties</p> </li> </ul> </li> <li> <p>used designs with randomised allocation of participants</p> </li> </ul> </p> <p>We settled differences in opinion by consensus with a third review author (SF). After the exclusion of non‐relevant publications and duplicates, we assessed the full‐text versions of the remaining papers against the inclusion and exclusion criteria, extracted data and entered them into standardised data extraction tables. We recorded the selection process in a PRISMA flow chart according to <a href="./references#CD009669-bbs2-0072" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):1-6.">Moher 2009</a> (<a href="#CD009669-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009669-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009669-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD009669-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the details of study population, interventions and outcomes (JS plus KU). The data extraction tables included the following items. </p> <p> <ul id="CD009669-list-0009"> <li> <p>General information: title, authors, source, contact address, country, published or unpublished, language and year of publication, sponsoring of trial </p> </li> <li> <p>Trial characteristics including study design, timing and follow‐up, quality assessment as specified below </p> </li> <li> <p>Participants: inclusion and exclusion criteria, definition of indication, baseline characteristics, similarity of groups at baseline, number of people eligible/randomised/completing/analysed, reasons for withdrawals/loss to follow‐up </p> </li> <li> <p>Interventions: dosage, route and timing of drug therapy/comparison intervention</p> </li> <li> <p>Outcomes: participants per group, mortality at specific time points, adverse effects (with definitions, methods for monitoring), MACE, haemodynamics (cardiac index, PCWP, MAP), length of hospital and ICU stay, quality of life, costs </p> </li> </ul> </p> </section> <section id="CD009669-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JS plus KU) independently assessed the internal validity of eligible studies according to the Cochrane 'Risk of bias' tool (<a href="./references#CD009669-bbs2-0057" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), resolving any disagreements by discussion until consensus was obtained. We described risk of bias and judged it as high, low or unclear in six specific domains: </p> <p> <ul id="CD009669-list-0010"> <li> <p>random sequence generation</p> </li> <li> <p>allocation concealment</p> </li> <li> <p>blinding of participants, personnel and outcome assessment</p> </li> <li> <p>incomplete outcome data addressed</p> </li> <li> <p>selective reporting</p> </li> <li> <p>other sources of bias (cross‐over design, baseline differences regarding the most important prognostic factors, conduct of the study affected by interim results, deviation from the study protocol not reflecting clinical practice, inappropriate administration of an intervention, contra‐active or similar pre‐randomisation intervention) </p> </li> </ul> </p> <p>We used the following items to assess the risk of bias of adverse events reporting with the response options low or high risk of bias or unclear risk of bias (<a href="./references#CD009669-bbs2-0057" title="HigginsJP , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). </p> <p> <ul id="CD009669-list-0011"> <li> <p>Are definitions of reported adverse events given?  </p> </li> <li> <p>Were the methods that were used for monitoring adverse events reported (e.g. use of prospective or routine monitoring; spontaneous reporting; participant checklist, questionnaire or diary; systematic survey of participants)? </p> </li> <li> <p>Were any participants excluded from the adverse events analysis?</p> </li> <li> <p>Does the report provide numerical data by intervention group?</p> </li> <li> <p>Which categories of adverse events were reported by the investigators?</p> </li> </ul> </p> </section> <section id="CD009669-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We presented dichotomous data (such as all‐cause mortality, frequencies of MACE events) as risk ratios (RRs) with their 95% confidence intervals (CIs) and continuous data (such as haemodynamic measures) as mean differences and 95% CIs. The data on haemodynamics (cardiac index, PCWP, MAP) were reported differently for the included studies and are summarised in an additional table. No information on quality of life or costs was available from the eligible trials. </p> </section> <section id="CD009669-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Participants were randomised into treatment groups. The unit of analysis was the individual participant with one single measurement for each outcome. As we only included RCTs with a parallel design, unit of analysis issues did not occur. </p> </section> <section id="CD009669-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If data were not available in the trial report or data collection, we contacted the trial investigators to provide missing data. </p> </section> <section id="CD009669-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>This systematic review brings together diverse material, with studies differing in the participants, interventions and exposure times, therefore we did not expect a single‐study effect and planned to apply a random‐effects model. To quantify the extent of variability among the studies, we planned to estimate the Q‐test for heterogeneity in order to quantify heterogeneity as a proportion of variability with Thompson’s I<sup>2</sup> statistic and to calculate the between‐study variance τ<sup>2</sup> (<a href="./references#CD009669-bbs2-0056" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21:1539-58.">Higgins 2002</a>; <a href="./references#CD009669-bbs2-0084" title="RückerG , SchwarzerG , SchumacherM . Heterogeneity in meta-analysis: misconceiving I2 . Evidenz, Fortbildung und Qualität im Gesundheitswesen2008;Suppl VI:20.">Rücker 2008</a>). Thresholds used for interpretation of I<sup>2</sup> were: 0% to 40% low heterogeneity, 30% to 60% moderate heterogeneity, 50% to 90% substantial heterogeneity, 75% to 100% considerable heterogeneity. Since the improtance of the observed value of I<sup>2</sup> depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity those factors were taken into account in the categorization. In case of considerable heterogeneity results were reported by trial rather than the summary effect measure. </p> <p>The following factors are possible sources of clinically relevant heterogeneity and we have summarised them in the table <a href="./references#CD009669-sec-0206" title="">Characteristics of included studies</a>. </p> <p> <ul id="CD009669-list-0012"> <li> <p>Different variations of standard therapies (other vasoactive drugs, re‐vascularisation, intra‐aortal balloon pump (IABP), mechanical ventilation, renal replacement therapy) </p> </li> <li> <p>Different variations of the experimental intervention (doses and scheduling)</p> </li> <li> <p>Different variations of control groups (treatment without investigated single drugs or combinations, treatment with placebo or no treatment) </p> </li> <li> <p>Differences in outcome‐relevant prognostic factors (age, gender, comorbidities, cardiac index, ejection fraction, time from symptom onset to intervention) </p> </li> <li> <p>Different definition of the indication (CS versus LCOS)</p> </li> <li> <p>Quality of studies</p> </li> </ul> </p> </section> <section id="CD009669-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>The use of funnel plots for the graphical detection of publication bias was not possible due to the small number of eligible trials. </p> </section> <section id="CD009669-sec-0035"> <h4 class="title">Data synthesis</h4> <p>The data we extracted from randomised studies was based on the intention‐to‐treat (ITT) principle. We undertook meta‐analyses using a random‐effects model with reference to the expected clinical heterogeneity of the comparable studies arising from differences in study characteristics and the associated assumption that the effects being estimated in the different studies were not identical but followed some distribution. </p> </section> <section id="CD009669-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses for all‐cause mortality with regard to sex, age, and cause of LCOS/CS. However, due to lack of available data, no subgroup analyses were conducted. </p> </section> <section id="CD009669-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis by comparing results of the random‐effects model and the fixed‐effect model. </p> </section> <section id="CD009669-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created 'Summary of findings' tables using GRADEpro GDT (<a href="./references#CD009669-bbs2-0045" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>) to summarise evidence and included our primary outcome (all‐cause mortality) (<a href="./references#CD009669-bbs2-0046" title="GuyattG , OxmanAD , AklE , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011a</a>; <a href="./references#CD009669-bbs2-0052" title="GuyattGH , OxmanAD , SantessoN , HeflandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology2013;66(2):158-72.">Guyatt 2013</a>). We used the five GRADE considerations (study limitations, inconsistency, imprecision, indirectness and other considerations) to rate our overall confidence in effect estimates. We used methods and recommendations as described in GRADE to rate the quality of evidence (<a href="./references#CD009669-bbs2-0030" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>; <a href="./references#CD009669-bbs2-0047" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011b</a>; <a href="./references#CD009669-bbs2-0048" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407-15.">Guyatt 2011c</a>; <a href="./references#CD009669-bbs2-0049" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology2011;64(12):1294-302.">Guyatt 2011d</a>; <a href="./references#CD009669-bbs2-0050" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303-10.">Guyatt 2011e</a>; <a href="./references#CD009669-bbs2-0051" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277-82.">Guyatt 2011f</a>) and justified all decisions to downgrade the quality of evidence using footnotes. We added comments to aid the reader's understanding of the review where necessary (<a href="./references#CD009669-bbs2-0087" title="SantessoN , Carrasco-LabraA , LangendamM , Brignardello-PetersenR , MustafaRA , HeusP , et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. Journal of Clinical Epidemiology2016;74:28-39.">Santesso 2016</a>). </p> <p>To estimate the assumed risk of death in the control group, we used the median risk among control groups from the included studies to describe the baseline risk for people with CS or LCOS. Due to the small size of some of the included studies, we also used the control group risk from a well‐designed observational study to describe the high baseline risk of mortality for people with LCOS/CS having standard cardiac care (<a href="./references#CD009669-bbs2-0090" title="SinghM , WhiteJ , HasdaiD , HodgsonPK , BergerPB , TopolEJ , et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock. Journal of the American College of Cardiology2007;50(18):1752–8.">Singh 2007</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009669-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009669-sec-0039"></div> <section id="CD009669-sec-0040"> <h3 class="title">Description of studies</h3> <p>Randomised controlled trials (RCTs) in people with AMI, HF or cardiac surgery complicated by CS or LCOS. </p> <section id="CD009669-sec-0041"> <h4 class="title">Results of the search</h4> <p>The previous version of this review included 13 studies. We updated the searches to identify any new potentially relevant references and identified a total of 3524 references after duplicates had been removed. In total, we thought 31 papers were of relevance and assessed them against the inclusion and exclusion criteria. Of these, 19 studies (reported in 22 papers) met our predefined inclusion criteria (see <a href="./references#CD009669-sec-0206" title="">Characteristics of included studies</a>). The remaining studies are listed in <a href="./references#CD009669-sec-0207" title="">Characteristics of excluded studies</a>. We recorded the process in a PRISMA flow chart (<a href="#CD009669-fig-0001">Figure 1</a>). </p> </section> <section id="CD009669-sec-0042"> <h4 class="title">Included studies</h4> <p>Nineteen randomised controlled trials met the inclusion criteria. Four of these investigated people with AMI complicated by CS or LCOS (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>), seven investigated people with acute HF complicated by CS or LCOS (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>), and eight investigated people with cardiac surgery complicated by CS or LCOS (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>; <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). </p> <p>The majority of published clinical trials examined levosimendan (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). Five trials investigated enoximone (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). There were only two trials investigating epinephrine (<a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>), one trial investigating dopexamine (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>), one trial investigating milrinone (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>) and one trial investigating dopamine plus milrinone (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>). Control group participants were treated with dobutamine (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>), dopamine (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>), dopamine plus dobutamine (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>), enoximone (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>), norepinephrine (<a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>), norepinephrine plus dobutamine (<a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>), piroximone (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>), epinephrine plus nitroglycerine (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>) or placebo (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). </p> <p>Twelve studies were conducted as single‐centre trials in France (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>), Spain (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>), Germany (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>), Austria (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>), Greece (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>), Norway (<a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>) and the UK (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>). Seven studies were conducted as multicentre trials in Argentina (<a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>), France (<a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>), the UK (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>), the USA (<a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>), the Netherlands plus Belgium (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>), Europe (<a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>) or Europe, Israel and Russia (<a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>). </p> <p>Trials acknowledging funding by the pharmaceutical industry were <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> (supported by Sanofi Winthrop Limited and statistical advice from J.M. White Associate); <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> (supported by Orion Pharma, Ercopharma and Quintiles/Innovex); <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> (supported by Orion Pharma); <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a> (author associated with Merrell Dow), <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> (supported by INSERM‐DHOS; authors associated with Pulsion, Baxter, Orion, Lilly, Novartis, Aguettant, Merck, Sharp and Dohme, Gilead, Relypsa, AstraZeneca, Grünenthal, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor, CTMA, Bayer, CVRx, CardioRenal, Servier, Abbott, Roche, Bristol Myers Squibb, Adrenomed, Neurotronik, Sanofi, Sphyngotec); <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> (supported by Orion Pharma, Abbott Laboratories and ICON Clinical Research; authors associated with Orion Pharma, Abbott, Protein Design Biopharma, Sigma‐Tau, Guidant, Edwards Life Sciences, Scios, Medtronic, Pfizer, AstraZeneca, Amgen, Takeda, Menarini); <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a> (supported by Merrel Dow) and <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a> (authors associated with Merrell Dow). In <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>, conflict of interest was not disclosed. </p> <p>Each study characteristic is presented briefly in the table <a href="./references#CD009669-sec-0206" title="">Characteristics of included studies</a>. We included information from two secondary publications of two eligible trials (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>). A more comprehensive assessment of the included studies is given below. </p> <section id="CD009669-sec-0043"> <h5 class="title">Participants</h5> <p>Altogether, 1979 participants were enrolled in the trials on levosimendan; 1005 were treated with levosimendan, and 974 served as controls and were treated with dobutamine (23 participants in <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>, 20 participants in <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>, 100 participants in <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, 11 participants in <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>, 68 participants in <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, 660 participants in <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>); enoximone (16 participants in <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>); or placebo (23 participants in <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>, five participants in <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>, 48 participants in <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> investigated 61 participants with AMI complicated by acute HF. The trial authors provided individual personal data on all participants with CS. 109 participants were enrolled in trials on enoximone; 54 were treated with enoximone, and 55 served as controls and were treated with dobutamine (19 participants in <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>, 10 participants in <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>, 10 participants in <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>); piroximone (10 participants in <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>); or epinephrine plus nitroglycerine (six participants in <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). Eighty‐seven participants were enrolled in trials on epinephrine; 42 were treated with epinephrine and 45 served as controls and were treated with norepinephrine (30 participants in <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>) or norepinephrine plus dobutamine (15 participants in <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>). One trial on dopexamine (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>) included 70 participants with 35 of them receiving dopamine as control. One trial on milrinone (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>) included 120 participants with 60 of them receiving dobutamine as control. One trial on dopamine plus milrinone (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>) included 20 participants with 10 of them receiving dopamine plus dobutamine as control. </p> <p>The mean or median age varied between 56 and 73 years. <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> excluded participants under 20 years of age, <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> excluded participants under 21 years of age and <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> excluded participants over 75 years of age. In all other trials, adult patients (aged 18 years and over) with no age restriction were enrolled. Between 30% (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>) and 87% (<a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>) of participants in the included trials were male. </p> <p>Time of randomisation varied between trials. Participants in <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> had to be included within two hours following PCI and 24 hours of CS, participants in <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> had to be included within 24 hours and participants in <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> within 48 hours following PCI. Participants in <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> were eligible with acute AMI within the past two weeks. Participants in <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> had to be included within four hours and participants in <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> within six hours post‐cardiac surgery. Participants in <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> had to be included within two hours after separation from cardiopulmonary bypass and at least 15 minutes after protamine administration. Information concerning time of randomisation was unavailable in <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>, <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>, <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>, <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>, <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>, <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>, <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>, <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>, <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> and <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>. </p> <p>Baseline MAP varied between 55 ± 9 mmHg and 54 ± 8 mmHg in <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>'s two treatment groups, and 81 ± 16 mmHg and 88 ± 15 mmHg in <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>'s two treatment groups. Baseline CI varied between 1.6 ± 0.4 L/min/m<sup>2</sup> in both treatment groups of <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>, and 2.3 (interquartile range (IQR) 2.1 to 2.5) L/min/m<sup>2</sup> and 2.2 (IQR 1.7 to 2.4) L/min/m<sup>2</sup> in the two treatment groups of <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>. Baseline PCWP varied between 10.3 ± 2.7 mmHg and 10.1 ± 1.3 mmHg in the two treatment groups of <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a> and 28.2 ± 7.9 mmHg and 31.0 ± 6.7 mmHg in the two treatment groups of <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>. Information concerning baseline MAP, CI or PCWP was unavailable in <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>. </p> <p>According to the inclusion and exclusion criteria described, 12 studies included solely participants suffering from LCOS (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>; <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>), six studies included solely participants suffering from CS (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>) and one study included participants suffering from either LCOS or CS (<a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>). </p> </section> <section id="CD009669-sec-0044"> <h5 class="title">Interventions</h5> <p>Nine included trials investigated the efficacy and safety of the calcium‐sensitiser levosimendan in combination with established therapeutic regimens. The comparisons were the following. </p> <p> <ul id="CD009669-list-0013"> <li> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>: levosimendan (10 min intravenous injection of 6 µg/kg followed by a continuous 24 h infusion at 0.1 µg/kg/min) compared with either placebo (continuous 24 h infusion of dextrose 5%) or dobutamine (continuous 24 h infusion at 5 µg/kg/min; if a symptomatic reduction was not achieved after 2 h, the rate of dobutamine infusion was gradually doubled) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>: levosimendan (loading dose of 12 µg/kg over 15 – 20 min followed by continuous infusion of 0.2 µg/kg/min for 24 h) compared with dobutamine (continuous infusion of 7.5 µg/kg/min for 24 h) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>: levosimendan (loading dose of 24 µg/kg over 10 min followed by continuous infusion of 0.1 µg/kg/min for 24 h) compared with dobutamine (continuous infusion of 5 µg/kg/min for 24 h); the infusion rate of either levosimendan or dobutamine was doubled if an adequate haemodynamic response was not achieved after 2 h </p> </li> <li> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>: levosimendan (front loading of 12 µg/kg over 10 min followed by 0.1 µg/kg/min for 50 min and 0.2 µg/kg/min infused for 23 h) compared with enoximone (fractional bolus of 0.5 µg/kg over 30 min followed by 2 to 10 µg/kg/min continuously titrated to the best haemodynamic response) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>: levosimendan (loading dose of 24 µg/kg over 10 min followed by continuous infusion of 0.1 µg/kg/min for 24 h) compared with dobutamine (continuous 24 h infusion at 5 µg/kg/min; if an adequate response (defined as an increase in CPO of at least 30%) was not achieved after 2 h, the rate of dobutamine infusion was doubled until the desired haemodynamic response was achieved) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>: levosimendan (0.2 µg/kg/min for 1 h followed by 0.1 µg/kg/min for 24 h) compared with placebo (infusion for 25 h matching size, colour of solution and packaging) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>: levosimendan (loading dose of 10 µg/kg over 1 h followed by continuous infusion of 0.1 µg/kg/min for 24 h) compared with dobutamine (continuous 24 h infusion at 5 µg/kg/min; if a favourable haemodynamic response was not observed the dose was increased successively to 7.5/10/12.5 µg/kg/min at 15 min intervals) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>: levosimendan (loading dose of 12 µg/kg over 10 min followed by an infusion of 0.1 µg/kg/min for 50 min followed by an infusion of 0.2 µg/kg/min for 23 h) compared with dobutamine (infusion initiated at 5 µg/kg/min; dose could be increased at the discretion of the investigator to a maximum rate of 40 µg/kg/min; infusion was maintained as long as clinically appropriate (minimum 24 h) and was tapered according to each participant`s clinical status) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>: levosimendan (bolus of 6 µg/kg followed by a continuous infusion initially at a rate of 0.1 µg/kg/h; at hourly intervals a repeated bolus (6 µg/kg) was given and the infusion rate was increased by increments of 0.1 µg/kg; up‐titration was continued until a maximum rate of 0.4 µg/kg/min was achieved or a dose‐limiting event (HR &gt; 130 beats per minute (bpm) or an increase in HR of &gt; 15 bpm above baseline for 10 min; symptomatic hypotension or a drop in SBP to &lt; 75 mmHg; decrease in PCWP to ≤ 10 mmHg; any adverse event that in the opinion of the site investigator required drug dose modification) occurred); if a dose‐limiting event occurred the study drug was discontinued until the event resolved and was then restarted at the next lower dose compared with placebo </p> </li> </ul> </p> <p>Five included trials investigated the efficacy and safety of enoximone:</p> <p> <ul id="CD009669-list-0014"> <li> <p><a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>: enoximone (bolus of 1 mg/kg for 10 min followed by a continuous infusion of 5 to 10 µg/kg/min for at least 24 h according to each participant`s clinical status) compared with dobutamine (continuous infusion of 5 to 10 µg/kg/min for at least 24 h according to each participant`s clinical status) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>: enoximone (loading dose of 50 µg/kg/min over 30 min followed by an infusion of 10 µg/kg/min for 12 h) compared with dobutamine (infusion of 10 µg/kg/min for 12 h) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>: enoximone (bolus of 0.5 to 1 mg/kg followed by a continuous infusion of 2 to 20 µg/kg/min as required to achieve an increase in CI of at least 30 % by the end of the first hour; the study period lasted 14 h) compared with dobutamine (continuous infusion of 5 to 15 µg/kg/min as required to achieve an increase in CI of at least 30% by the end of the first hour; the study period lasted 14 h) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>: enoximone (loading dose of 0.5 mg/kg over 20 min followed by an infusion of 5 µg/kg/h; the study period was until 3h after the start of infusion the study drug) compared with piroximone (loading dose of 0.5 mg/kg over 20 min followed by an infusion of 5 µg/kg/h; the study period was until 3 h after the start of infusion the study drug) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>: enoximone (bolus of 0.5 mg/kg over 10 min followed by an infusion of 5 µg/kg/min increased up to 20 µg/kg/min according to haemodynamic response (MAP 60 – 80 mmHg) for 4 h) compared with epinephrine‐nitroglycerine (epinephrine infusion starting with 0.05 µg/kg/min in combination with a nitroglycerin infusion of 0.5 µg/kg/min according to haemodynamic response (MAP 60 – 80 mmHg) for 4 h) </p> </li> </ul> </p> <p>Two included trials investigated the efficacy and safety of epinephrine:</p> <p> <ul id="CD009669-list-0015"> <li> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>: epinephrine (initiated at 0.1 µg/kg/min; infusion rate was titrated at 5‐min intervals to a MAP between 65 and 70 mmHg with a stable or increased CI; tapering of study drug if the target MAP had been maintained for 8 h) compared with norepinephrine‐dobutamine (norepinephrine initiated at 0.1 µg/kg/min; infusion rate of norepinephrine was titrated at 5‐min intervals to a MAP between 65 and 70 mmHg with a stable or increased CI; infusion of dobutamine at a dose of up to 10 µg/kg/min; tapering of study drugs if the target MAP had been maintained for 8 h) </p> </li> <li> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>: epinephrine (continuous infusion increased by 0.02 µg/kg/min (or higher in emergency cases) to the targeted MAP of 65 – 70 mmHg; a participant was considered to be weaned from vasopressor therapy after 24 h of haemodynamic stability without vasopressor support – during this time lag, if MAP decreased to &lt; 65 – 70 mmHg, the study drug was reintroduced; the study period lasted a maximum of 60 days) compared with norepinephrine (continuous infusion increased by 0.02 µg/kg/min (or higher in emergency cases) to the targeted MAP of 65 – 70 mmHg; a participant was considered to be weaned from vasopressor therapy after 24 h of haemodynamic stability without vasopressor support – during this time lag, if MAP decreased to &lt; 65 – 70 mmHg, the study drug was reintroduced; the study period lasted a maximum of 60 days) </p> </li> </ul> </p> <p>One included trial investigated the efficacy and safety of dopexamine:</p> <p> <ul id="CD009669-list-0016"> <li> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>: dopexamine (titration in 3 steps each at 15 min intervals: 0.5/1.0/2.0 µg/kg/min until CI was &gt; 2.5 L/min/m<sup>2</sup>; continuous infusion at effective dose level for 6 h) compared with dopamine (titration in 3 steps each at 15‐min intervals: 1.5/3.0/6.0 µg/kg/min until CI was &gt; 2.5 L/min/m<sup>2</sup>; continuous infusion at effective dose level for 6 h) </p> </li> </ul> </p> <p>One included trial investigated the efficacy and safety of milrinone:</p> <p> <ul id="CD009669-list-0017"> <li> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>: milrinone (loading dose of 50 µg/kg over 10 min followed by an infusion of 0.5 µg/kg/min; after 1 h an upward dose adjustment could be made if clinically indicated by giving a second loading dose (50 µg/kg over 10 min) and an infusion of 0.75 µg/kg/min; the study drug was continued as long as clinically indicated) compared with dobutamine (continuous infusion started at 10 µg/kg/min; at 15‐min intervals an upward dose adjustment to 15 µg/kg/min, then 20 µg/kg/min could be made if clinically indicated; the study drug was continued as long as clinically indicated) </p> </li> </ul> </p> <p>One included trial investigated the efficacy and safety of dopamine‐milrinone:</p> <p> <ul id="CD009669-list-0018"> <li> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>: dopamine‐milrinone (continuous infusion of dopamine (10 – 12 µg/kg/min for 4 h) combined with a loading dose of milrinone (50 µg/kg over 10 min) followed by an continuous infusion of milrinone (0.5 µg/kg/min for 4 h)) compared with dopamine‐dobutamine (continuous infusion of dopamine (10 – 12 µg/kg/min for 4 h) combined with a continuous infusion of dobutamine in cumulatively increasing dosage of 3/6/9 µg/kg/min in 20‐minute intervals each; from 1 h maintenance dose of 9 µg/kg/min dobutamine for further 3 h) </p> </li> </ul> </p> </section> </section> <section id="CD009669-sec-0045"> <h4 class="title">Excluded studies</h4> <p>We excluded six trials because they were not RCTs (<a href="./references#CD009669-bbs2-0022" title="El Mokhtari Nour Eddine, ArltA , MeissnerA , LinsM . Inotropic therapy for cardiac low output syndrome. European Journal of Medical Research2007;12(11):563-7. ">El Mokhtari 2007</a>; <a href="./references#CD009669-bbs2-0023" title="PomerS , ElertO , SaraiK , SatterP . Comparative effects of combined dopamine and nitroprusside versus dobutamine and nitroprusside infusions for computer-controlled management of low-output cardiac failure after open heart surgery. International Journal of Clinical Pharmacology, Therapy, and Toxicology1986;24(2):77-81. ">Pomer 1986</a>; <a href="./references#CD009669-bbs2-0024" title="RychterJ , IwaszkiewiczA , GolanskiR , RybinskiL , KesiakJ , TomaszewskaL . Nitroglycerin and dobutamine in the treatment of low cardiac output syndrome after direct myocardial revascularization. Wplyw Glukagonu na Uklad Krazenia1985;40(5):135-7. ">Rychter 1985</a>) or due to wrong indication (<a href="./references#CD009669-bbs2-0020" title="Al-ShawafE , AyedA , VislockyI , RadomirB , DehrabN , TaraziR . Levosimendan or milrinone in the type 2 diabetes patient with low ejection fraction undergoing elective coronary artery surgery. Journal of Cardiothoracic and Vascular Anesthesia2006;20:353-7. ">Al‐Shawaf 2006</a>; <a href="./references#CD009669-bbs2-0021" title="DupuisJY , BondyR , CattranC , NathanHJ , WynandsJE . Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery. Journal of Cardiothoracic and Vascular Anesthesia1992;6(5):542-53. ">Dupuis 1992</a>; <a href="./references#CD009669-bbs2-0025" title="SeinoY , MomomuraS , TakanoT , HayakawaH , KatohK , Japan Intravenous Milrinone Investigators. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Intensive Care Medicine1996;24(9):1490-7. ">Seino 1996</a>). Reasons for exclusion are presented briefly in tabulated form (see <a href="./references#CD009669-sec-0207" title="">Characteristics of excluded studies</a>). </p> <section id="CD009669-sec-0046"> <h5 class="title">Ongoing studies</h5> <p>We identified three ongoing studies investigating milrinone versus dobutamine for LCOS/CS treatment (<a href="./references#CD009669-bbs2-0026" title="NCT03207165. Milrinone versus dobutamine in critically ill patients. clinicaltrials.gov/show/NCT03207165 (first received 2 July 2017). ">NCT03207165</a>), norepinephrine versus norepinephrine‐dobutamine for CS treatment (<a href="./references#CD009669-bbs2-0027" title="NCT03340779. Norepinephrine vs norepinephrine and dobutamine in cardiogenic shock. clinicaltrials.gov/show/NCT03340779 (first received 14 November 2017). ">NCT03340779</a>) or levosimendan versus placebo for CS treatment (<a href="./references#CD009669-bbs2-0028" title="NCT04020263. Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. clinicaltrials.gov/show/NCT04020263 (first received 16 July 2019). ">NCT04020263</a>). For details of the planned investigations in tabulated form, please see <a href="./references#CD009669-sec-0208" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD009669-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>All trials were published in peer‐reviewed journals. Included trials were small with the exception of <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>, which enrolled 1320 participants. In all trials, analysis was done by intention‐to‐treat. <a href="#CD009669-fig-0002">Figure 2</a> and <a href="#CD009669-fig-0003">Figure 3</a> present a summary of all investigated sources of bias in the 19 eligible studies. The 'Risk of bias' tables of the individual trials are given in <a href="./references#CD009669-sec-0206" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD009669-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009669-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD009669-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD009669-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD009669-sec-0048"> <h4 class="title">Allocation</h4> <p>Risk of bias for random sequence generation was rated low for 10 studies, unclear for eight studies (no information provided), and high for one study (inappropriate approach). Risk of bias for allocation concealment was rated low for five studies, unclear for five studies (no information provided), and high for nine studies (open‐label trials without concealment). </p> <p>The method of random sequence generation was reported in 11 trials (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>; <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>). A block randomisation by means of a computer‐generated code was used by <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> and <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> with <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> using an extra stratum for participants with CS. Drawing of lots was performed by <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a> and <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a> and shuffling of envelopes by <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>. <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> randomised participants centrally using an interactive voice‐response system, which was stratified by a biased coin algorithm with previous acute decompensated heart failure and country as factors. An inadequate method of sequence generation, i.e. assignment based on date of birth, was used by <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>. </p> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> and <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> described the method of allocation concealment. Allocation was performed by a blinded investigator according to a pre‐determined list. No information was available from <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> and <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>. All other studies were assigned as open‐label trials without concealment. </p> </section> <section id="CD009669-sec-0049"> <h4 class="title">Blinding</h4> <p>Risk of bias for blinding of participants and personnel was rated low for six studies and high for 13 studies (open‐label trials or different administration of the study drug). Risk of bias for outcome assessment was rated low for seven studies, unclear for three studies (no information provided), and high for nine studies (open‐label trials without concealment). </p> <p>Risk of bias due to performance or detection was low in <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> and <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>. In <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a> and <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>, outcome assessment was blinded but not personnel/participants. In <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>, personnel/participants were blinded, but blinding of outcome assessment was opened. In all other studies, blinding was either not performed or not possible due to different administration of the study drug. </p> </section> <section id="CD009669-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of bias for incomplete outcome data was rated low for 14 studies and high for five studies (exclusion of participants with no data reported for these participants). </p> <p>In sum, eight studies reported exclusion of participants (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> reported haemodynamic changes in 36 participants but randomised only 32 participants. </p> </section> <section id="CD009669-sec-0051"> <h4 class="title">Selective reporting</h4> <p>Risk of bias for selective reporting was rated low for all studies. All outcomes prespecified in the method sections were reported, however, prespecified secondary endpoints were missing in <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> and <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>. </p> </section> <section id="CD009669-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Risk of bias for other potential sources of bias was rated low for nine studies, unclear for two studies (affected by interim results), and high for eight studies (inappropriate delivery and interruptions of study drug administration, concerns regarding the eligibility of the included participant). </p> <p>None of the included trials reported any cross‐over or deviation from the study protocol.</p> <p>The conduct of three trials was affected by interim results. <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> was stopped as a result of an interim analysis performed after recruitment of 32 participants in consultation with the ethics committee due to a trend towards reduced mortality for levosimendan. <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> was terminated prematurely by the data and safety monitoring board given the higher incidence of refractory shock in the epinephrine group. In <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>, the originally targeted number of participants (n = 700) was increased to 1320 following a blinded review of mortality after 131 deaths to achieve the target number of 330 deaths. </p> <p>Seven trials reported inappropriate delivery and interruptions of study drug administration (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). </p> <p>All trials addressed the problem of pre‐randomisation drug‐treatment strategies. Most of the included participants were not randomised to the study drug at the index event (onset of LCOS/CS) and they were therefore pretreated with different inotropic and vasoactive drugs, which could have influenced microcirculation and thereby affected prognosis. </p> <p>To the best of our knowledge, no trial used a complex standardised study protocol for vasopressor titration for the assessment of the lowest necessary vasopressor dosage in each individual participant. </p> <p>Although the title and inclusion criteria of the study conducted by <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> implied that the enrolled participants suffered from CS, there remained major concerns regarding the eligibility of the included participants. This was because none of them developed multi‐organ failure and the mortality rates appeared very low in comparison to commonly reported data. </p> <section id="CD009669-sec-0053"> <h5 class="title">Bias affecting the quality of evidence on adverse events</h5> <p>Risk of bias for adverse events was rated low for nine studies and high for 10 studies (none or very limited monitoring). </p> <p>Reports on adverse events were missing in two trials (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>). <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> and <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> reported on previously defined adverse events but only <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> and <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> gave definitions of the reported adverse events. In <a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>, solely all‐cause mortality within stay at the ICU was monitored. In <a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>, a report of adverse events was limited to those occurring in more than five participants and in <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> to those occurring within 6 h. In <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a> and <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>, monitoring was restricted to spontaneous reports of some adverse events which occurred. None of the studies (with the limitation of <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> and <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>, who have not provided any information) excluded participants from adverse event analysis. </p> </section> </section> </section> <section id="CD009669-sec-0054"> <h3 class="title" id="CD009669-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD009669-tbl-0001"><b>Summary of findings 1</b> Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0002"><b>Summary of findings 2</b> Levosimendan compared to placebo for cardiogenic shock or low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0003"><b>Summary of findings 3</b> Levosimendan compared to enoximone for cardiogenic shock</a>; <a href="./full#CD009669-tbl-0004"><b>Summary of findings 4</b> Epinephrine compared to norepinephrine‐dobutamine for cardiogenic shock</a>; <a href="./full#CD009669-tbl-0005"><b>Summary of findings 5</b> Dopexamine compared to dopamine for low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0006"><b>Summary of findings 6</b> Milrinone compared to dobutamine for low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0007"><b>Summary of findings 7</b> Enoximone compared to dobutamine for low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0008"><b>Summary of findings 8</b> Epinephrine compared to norepinephrine for cardiogenic shock</a>; <a href="./full#CD009669-tbl-0009"><b>Summary of findings 9</b> Dopamine‐milrinone compared to dopamine‐dobutamine for cardiogenic shock</a>; <a href="./full#CD009669-tbl-0010"><b>Summary of findings 10</b> Enoximone compared to piroximone for low cardiac output syndrome</a>; <a href="./full#CD009669-tbl-0011"><b>Summary of findings 11</b> Enoximone compared to epinephrine‐nitroglycerine for low cardiac output syndrome</a> </p> <section id="CD009669-sec-0055"> <h4 class="title">1. Levosimendan versus dobutamine</h4> <p>Three small, single‐centre trials with 109 participants (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>) as well as three multicentre trials with 1660 participants (<a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>) investigated levosimendan compared with dobutamine in people with AMI (<a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>), acute HF (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>) or cardiac surgery (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>) complicated by CS/LCOS (<a href="./full#CD009669-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD009669-sec-0056"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0057"> <h6 class="title">Short‐term</h6> <p>Levosimendan when compared to dobutamine may reduce all‐cause mortality in the short term with 94 deaths out of 853 participants (11.0%) in the intervention arm with levosimendan compared with 126 deaths out of 848 participants (14.9%) in the control group treated with dobutamine (RR 0.60, 95% CI 0.36 to 1.03; participants = 1701; studies = 4; low‐quality evidence) with moderate heterogeneity between single studies (I<sup>2</sup> = 46%) (<a href="./references#CD009669-fig-0004" title="">Analysis 1.1</a>). Out of 1000 people with CS, approximately 148 would be expected to die with standard cardiac care with dobutamine within a short‐term follow‐up period compared to 89 (95% CI 53 to 152) with levosimendan. </p> </section> <section id="CD009669-sec-0058"> <h6 class="title">Long‐term</h6> <p>Levosimendan when compared to dobutamine may make little or no difference in the long‐term with 205 deaths out of 797 participants (25.7%) in the intervention arm with levosimendan compared with 229 deaths out of 794 participants (28.8%) in the control group treated with dobutamine (RR 0.84, 95% CI 0.63 to 1.13; participants = 1591; studies = 4; low‐quality evidence) with low heterogeneity between single studies (I<sup>2</sup> = 27%) (<a href="./references#CD009669-fig-0006" title="">Analysis 1.3</a>). Out of 1000 people, approximately 288 would be expected to die with standard cardiac care with dobutamine within a long‐term follow‐up period compared to 242 (95% CI 181 to 325) with levosimendan. </p> </section> <section id="CD009669-sec-0059"> <h6 class="title">Subgroup analyses</h6> <p>No subgroup analysis was performed due to the small number of studies.</p> <p>In one study (<a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>), the effect was compared according to sex and age. In this study, no interaction was observed. </p> </section> <section id="CD009669-sec-0060"> <h6 class="title">Sensitivity analyses</h6> <p>There were differences when fixed effects were used for short‐term mortality (smaller confidence interval) in favour of levosimendan (<a href="./references#CD009669-fig-0005" title="">Analysis 1.2</a>), however, due to moderate heterogeneity (I<sup>2 </sup>= 46%) this has to be interpreted with caution. Regarding short‐term mortality, sensitivity analysis showed no differences according to which statistical model was used (<a href="./references#CD009669-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD009669-sec-0061"> <h5 class="title">Major adverse cardiac events (MACE)</h5> <p>Information on MACE was restricted to <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> and <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>. Both <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> and <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> claimed that there were no MACE in either intervention arm; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> documented no re‐infarction or cerebrovascular accident in either group during hospitalisation. In <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, from the participants randomised to levosimendan, one out of 69 (1.4%) suffered from perioperative infarction and two out of 69 (2.9%) suffered from cerebrovascular accidents whereas, from the participants randomised to dobutamine, eight out of 68 (11.8%) and six out of 68 (8.8%) suffered from perioperative infarction and cerebrovascular accidents, respectively (<a href="./references#CD009669-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD009669-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD009669-sec-0062"> <h5 class="title">Length of hospital stay</h5> <p>Information on length of hospital stay was restricted to <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, which reported a shorter median intensive care unit (ICU) time in the levosimendan intervention arm compared to the dobutamine intervention arm, with high imprecision (66 h (IQR 58 to 74) compared to 158 h (106 to 182)). </p> </section> <section id="CD009669-sec-0063"> <h5 class="title">Quality of life</h5> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0064"> <h5 class="title">Haemodynamics</h5> <p>Information on CI was restricted to <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> and <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; information on PCWP was restricted to <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> and <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> and information on MAP was restricted to <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> and <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>. In both the analysis of CI and PCWP, the I<sup>2</sup> was considerable (94% and 76%, respectively) making it inappropriate to pool studies. The reported CI showed no differences in <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> (1.9 ± 0.47 versus 1.8 ± 0.19). However, differences were found in <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> and <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>: 2.8 ± 0.3 versus 2.3 ± 0.2; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>: 3.4 ± 0.2 versus 2.7 ± 0.1) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0010" title="">Analysis 1.7</a>). The reported PCWP showed differences in all three studies (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>: 19 ± 4.79 versus 23 ± 4.79; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>: 18 ± 8 versus 24 ± 7; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>: 12.1 ± 1 versus 15 ± 2) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0011" title="">Analysis 1.8</a>). The reported MAP indicated no differences between groups in <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> (78.8 ± 7 versus 80.1 ± 4) but did find differences between groups in <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> (77 ± 5 versus 81 ± 7) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0012" title="">Analysis 1.9</a>). </p> <div class="table" id="CD009669-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Haemodynamics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haemodynamics</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD (</b> 95% CI<b>)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention vs control</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>last measurements</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mean</b> ± <b>SD or median (IQR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mean</b> ± <b>SD or median (IQR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Levosimendan versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 ± 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.11 to 0.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 ± 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.34 to 0.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 ± 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 ± 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.65 to 0.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐6.77 to ‐1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.00 (‐8.07 to ‐3.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1 ± 1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.90 (‐3.43 to ‐2.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.0 ± 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐7.74 to ‐0.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.7 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.1 ± 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.30 (‐3.21 to 0.61)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Levosimendan versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.17 to 0.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (6 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.32 to 0.88)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐6.77 to ‐1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.0 ± 9.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.0 ± 6.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.0 (‐9.77 to ‐4.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.0 ± 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.0 ± 13.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.0 (‐9.54 to 1.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Levosimendan versus enoximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.5 ‐ 3.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.8 ‐ 3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (48 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.0 (16.0 ‐ 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 21.0 (19.0 ‐ 28.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.0 (58.0 ‐ 79.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.0 (63.0 ‐ 83.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Epinephrine versus norepinephrine‐dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (24 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 ± 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.22 to 0.42)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐5.01 to 5.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.0 ± 9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.0 (‐8.19 to 6.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dopexamine versus dopamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (6 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.02 to 0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.50 (‐2.93 to ‐0.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.3 ± 11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2 ± 12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.90 (‐7.60 to 3.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Milrinone versus dobutamine</b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (4 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 ± 0.77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 ± 2.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.92 to 0.32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (4 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2 ± 3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6 ± 5.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.40 (‐2.98 to 0.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (4 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.5 ± 21.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5 ± 32.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.0 (‐16.89 to 2.89)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Enoximone versus dobutamine</b><br/> <br/> <br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (12 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56 ± 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.74 (‐0.75 to 0.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (14 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 0.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.97 to 0.37) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (12 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 ± 5.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.7 ± 6.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.70 (‐9.11 to 1.71) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (14 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 ± 4.2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8 ± 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (‐3.34 to 3.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (12 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.0 ± 11.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 ± 17.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.0 (‐27.55 to ‐2.45) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> <b>Epinephrine versus norepinephrine</b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (1.9 ‐ 3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (2.2 ‐ 3.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5 ± 4.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 ± 5.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.30 (‐5.86 to ‐0.74) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (72 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.7 ± 12.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5 ± 8.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.20 (1.73 to 12.67) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dopamine‐milrinone versus dopamine‐dobutamine</b><br/> <br/> <br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (1 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 ± 0.31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 ± 0.63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.74 to 0.14) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (1 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.0 ± 4.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 6.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.0 (‐6.78 to 2.78) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (1 h after treatment initiation; mmHg)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0 ± 7.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0 ± 12.01 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0 (‐14.91 to 2.91) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Enoximone versus piroximone</b><br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (3 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 ± 0.5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 (‐0.50 to 0.30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (3 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.70 (‐2.41 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (3 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.9 ± 8.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.6 ± 7.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.30 (‐3.62 to 10.22)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/>IQR: interquartile range<br/>MAP: mean arterial pressure<br/>MD: mean difference<br/>PCWP: pulmonary capillary wedge pressure<br/>SD: standard deviation </p> </div> </div> </section> <section id="CD009669-sec-0065"> <h5 class="title">Costs</h5> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0066"> <h5 class="title">Adverse events</h5> <p>Adverse events were reported by <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> and (very detailed) <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>. In <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>, no adverse events occurred (<a href="#CD009669-tbl-0013">Table 2</a>). <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> reported a better safety profile of levosimendan compared to dobutamine (<a href="#CD009669-tbl-0013">Table 2</a>). In contrast, <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> and <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> did not observe marked differences in the safety profile of the drugs compared (<a href="#CD009669-tbl-0013">Table 2</a>). </p> <div class="table" id="CD009669-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> (no MACE) </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> </tr> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="48" valign=""> <p><b>Levosimendan versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute kidney failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (7.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> <p>(30.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (2.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angina pectoris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>680</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>, <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (8.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>848</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Congestive) cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 (16.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134 (20.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (4.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disorder aggravated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1,9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (4.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (2.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>728</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (7.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (9.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111 (14.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (12.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (5.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (4.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple organ failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle spasms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (6.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (7.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (11.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (1.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>728</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolonged ventilatory assistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (8.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (32.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (13.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic inflammatory response syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (5.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (22.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (11.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (11.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vasoplegia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (13.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>, <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (13.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Levosimendan versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (25.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>, <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Levosimendan versus enoximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute renal failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (31.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (56.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (81.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (93.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (18.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic inflammatory response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (81.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular tachycardia or fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (68.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Epinephrine versus norepinephrine‐dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supraventricular arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sustained ventricular tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (6.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Dopexamine versus dopamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal blood loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (11.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (8.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Junctional rhythm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premature atrial contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (17.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premature ventricular contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (25.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (31.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Milrinone versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (18.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (15.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (40.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oligouria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (8.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (18.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Enoximone versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatic cytolysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia and/or hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (21.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular hyperexcitability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Epinephrine versus norepinephrine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (40.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for extracorporeal life support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (11.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Refactory shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (37.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (6.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Enoximone versus piroximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Enoximone versus epinephrine/nitroglycerine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhytmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LIDO: study title ("levosimendan infusion versus dobutamine")<br/>MACE: major adverse cardiac events<br/>MAP: mean arterial pressure<br/>ST: segment of the electrocardiogram<br/>SURVIVE: study title ("survival of patients with acute heart failure in need of intravenous inotropic support") </p> </div> </div> </section> </section> <section id="CD009669-sec-0067"> <h4 class="title">2. Levosimendan versus placebo</h4> <p>Two small, single‐centre trials with 55 participants (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>) as well as one multicentre trial with 146 participants (<a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>) investigated levosimendan compared with placebo in the context of people suffering from AMI (<a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>) or acute HF (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>) complicated by LCOS/CS (<a href="./full#CD009669-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD009669-sec-0068"> <h5 class="title">All‐cause mortality</h5> <p>Information on mortality was restricted to two studies (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>). </p> <section id="CD009669-sec-0069"> <h6 class="title">Short‐term</h6> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0070"> <h6 class="title">Long‐term</h6> <p>We are uncertain about the effects on long‐term mortality with three deaths out of 27 participants (11.1%) in the intervention arm with levosimendan compared with six deaths out of 28 participants (21.4%) in the control group treated with placebo (RR 0.55, 95% CI 0.16 to 1.90; participants = 55; studies = 2; very low‐quality evidence) with low heterogeneity between single studies (I<sup>2</sup> = 0%) (<a href="./references#CD009669-fig-0013" title="">Analysis 2.1</a>). Out of 1000 people, approximately 218 would be expected to die with standard cardiac care with placebo within a long‐term follow‐up period compared to 118 (95% CI 35 to 407) with levosimendan. </p> </section> <section id="CD009669-sec-0071"> <h6 class="title">Subgroup analyses</h6> <p>No subgroup analysis was performed due to the small number of studies.</p> </section> <section id="CD009669-sec-0072"> <h6 class="title">Sensitivity analyses</h6> <p>Sensitivity analysis showed no differences according to which statistical model was used (<a href="./references#CD009669-fig-0014" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD009669-sec-0073"> <h5 class="title">MACE</h5> <p>Information on MACE was restricted to <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>. The authors claimed that there were no MACE in either intervention arm. </p> </section> <section id="CD009669-sec-0074"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0075"> <h5 class="title">Quality of life</h5> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0076"> <h5 class="title">Haemodynamics</h5> <p>Information on CI and PCWP was restricted to <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> and <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>; information on MAP was restricted to <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>. In the analysis of CI, the I<sup>2</sup> was considerable (83%) between single studies. The reported CI showed no differences in <a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> (1.9 ± 0.47 versus 1.8 ± 0.19). However, differences were found in <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> (2.5 ± 0.98 versus 1.9 ± 0.69) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0015" title="">Analysis 2.3</a>). The reported PCWP and MAP showed differences between participants randomised to levosimendan and placebo (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>: 19 ± 4.79 versus 23 ± 4.79; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>: PCWP: 21 ± 9.89 versus 28 ± 6.92; MAP: 81 ± 19.79 versus 85 ± 13.85) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0016" title="">Analysis 2.4</a>; <a href="./references#CD009669-fig-0017" title="">Analysis 2.5</a>). </p> </section> <section id="CD009669-sec-0077"> <h5 class="title">Costs</h5> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0078"> <h5 class="title">Adverse events</h5> <p>Information on adverse events was restricted to two studies (<a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). Reported adverse events included atrial fibrillation and ventricular tachycardia (<a href="#CD009669-tbl-0013">Table 2</a>). No intervention group was superior with regard to the safety profile. </p> </section> </section> <section id="CD009669-sec-0079"> <h4 class="title">3. Levosimendan versus enoximone</h4> <p>There was only one small, single‐centre study with 32 participants investigating levosimendan compared with enoximone in people with AMI complicated by CS (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>) (<a href="./full#CD009669-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD009669-sec-0080"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0081"> <h6 class="title">Short‐term</h6> <p>We are uncertain about the effects on short‐term mortality with five deaths out of 16 participants (31.3%) in the intervention arm with levosimendan compared with 10 deaths out of 16 participants (62.5%) in the control group treated with enoximone (RR 0.50, 0.22 to 1.14; participants = 32; studies = 1; very low‐quality evidence). Out of 1000 people, approximately 625 would be expected to die with standard cardiac care with enoximone within a short‐term follow‐up period compared to 313 (95% CI 138 to 712) with levosimendan (<a href="./references#CD009669-fig-0018" title="">Analysis 3.1</a>; <a href="./references#CD009669-fig-0019" title="">Analysis 3.2</a>). </p> </section> <section id="CD009669-sec-0082"> <h6 class="title">Long‐term</h6> <p>No results were available from the included studies.</p> </section> <section id="CD009669-sec-0083"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses. </p> </section> </section> <section id="CD009669-sec-0084"> <h5 class="title">MACE</h5> <p>From the participants randomised to enoximone one out of 16 (6.3%) suffered from MACE (cerebrovascular accidents) whereas no MACE were reported for participants randomised to levosimendan (<a href="./references#CD009669-fig-0020" title="">Analysis 3.3</a>). </p> </section> <section id="CD009669-sec-0085"> <h5 class="title">Length of hospital stay</h5> <p>A shorter median ICU time was reported in the levosimendan group compared to the enoximone group with high imprecision (10 days (IQR 5 to 23) compared to 13 days (IQR 7 to 19)). </p> </section> <section id="CD009669-sec-0086"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0087"> <h5 class="title">Haemodynamics</h5> <p>The reported CI showed no differences between participants randomised to levosimendan or enoximone (median CI 3.1 L/min/m<sup>2</sup> in both groups; IQR 2.5 to 3.5 on levosimendan versus 2.8 to 3.3 on enoximone) (<a href="#CD009669-tbl-0012">Table 1</a>). Small differences were found in PCWP and MAP (median PCWP 17 mmHg (IQR 16 to 20) on levosimendan versus 21 mmHg (IQR 19 to 28) on enoximone; median MAP 75 mmHg (IQR 58 to 79) on levosimendan versus 70 mmHg (IQR 63 to 83) on enoximone) (<a href="#CD009669-tbl-0012">Table 1</a>). </p> </section> <section id="CD009669-sec-0088"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0089"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included acute renal failure, atrial fibrillation, need of mechanical ventilation, pneumonia, sepsis, systemic inflammatory response, urinary infections and ventricular tachycardia or fibrillation (<a href="#CD009669-tbl-0013">Table 2</a>). Levosimendan showed a slightly better safety profile compared to enoximone. </p> </section> </section> <section id="CD009669-sec-0090"> <h4 class="title">4. Epinephrine versus norepinephrine‐dobutamine</h4> <p>There was only one small, single‐centre study with 30 participants investigating epinephrine compared with norepinephine‐dobutamine in the context of acute HF complicated by CS (<a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>) (<a href="./full#CD009669-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD009669-sec-0091"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0092"> <h6 class="title">Short‐term</h6> <p>We found no clear reported difference in short‐term mortality with five deaths out of 15 participants (33.3%) in the intervention arm with epinephrine compared with four deaths out of 15 participants (26.7%) in the control group treated with norepinephrine‐dobutamine (RR 1.25; 95% CI 0.41 to 3.77; participants = 30; studies = 1; very low‐quality evidence). Out of 1000 people, approximately 267 per 1000 would be expected to die with standard cardiac care with norepinephrine‐dobutamine within a short‐term follow‐up period compared to 333 (95% CI 109 to 1003) with epinephrine (<a href="./references#CD009669-fig-0021" title="">Analysis 4.1</a>; <a href="./references#CD009669-fig-0022" title="">Analysis 4.2</a>). </p> </section> <section id="CD009669-sec-0093"> <h6 class="title">Long‐term</h6> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0094"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses. </p> </section> </section> <section id="CD009669-sec-0095"> <h5 class="title">MACE</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0096"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0097"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0098"> <h5 class="title">Haemodynamics</h5> <p>The reported CI, PCWP and MAP showed no differences between participants randomised to either epinephrine or norepinephrine‐dobutamine (CI: 2.9 ± 0.5 versus 2.8 ± 0.4; PCWP: 18 ± 7 versus 18 ± 7; MAP: 64 ± 9 versus 65 ± 11) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0023" title="">Analysis 4.3</a>; <a href="./references#CD009669-fig-0024" title="">Analysis 4.4</a>; <a href="./references#CD009669-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD009669-sec-0099"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0100"> <h5 class="title">Adverse events</h5> <p>In the epinephrine group, two out of 15 (13.3%) participants suffered from supraventricular arrhythmia, and one out of 15 (6.7%) participants suffered from sustained ventricular tachycardia. No such adverse events were reported for the participants treated with norepinephrine‐dobutamine (<a href="#CD009669-tbl-0013">Table 2</a>). </p> </section> </section> <section id="CD009669-sec-0101"> <h4 class="title">5. Dopexamine versus dopamine</h4> <p>There was only one small, multicentre study with 70 participants investigating dopexamine compared with dopamine in the context of cardiac surgery complicated by LCOS (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>). No RR and resulting estimations on absolute risk reduction were possible (<a href="./full#CD009669-tbl-0005">summary of findings Table 5</a>). </p> <section id="CD009669-sec-0102"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0103"> <h6 class="title">Short‐term</h6> <p>The study reported that no deaths in hospital occurred in either intervention arm. We are uncertain about the effects due to very low quality of evidence. </p> </section> <section id="CD009669-sec-0104"> <h6 class="title">Long‐term</h6> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0105"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses. </p> </section> </section> <section id="CD009669-sec-0106"> <h5 class="title">MACE</h5> <p>Perioperative infarctions were reported for three out of 35 participants (8.6%) in the dopexamine intervention arm and two out of 35 (5.7%) participants in the dopamine intervention arm (<a href="./references#CD009669-fig-0026" title="">Analysis 5.1</a>). </p> </section> <section id="CD009669-sec-0107"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0108"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0109"> <h5 class="title">Haemodynamics</h5> <p>Small differences were found in CI and PCWP (CI: 3.1 ± 0.7 versus 2.8 ± 0.5; PCWP: 9.3 ± 3.2 versus 10.8 ± 2.9) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0027" title="">Analysis 5.2</a>; <a href="./references#CD009669-fig-0028" title="">Analysis 5.3</a>). The reported MAP showed no differences between participants randomised to dopexamine or dopamine (76.3 ± 11.5 versus 78.2 ± 12.8) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0029" title="">Analysis 5.4</a>). </p> </section> <section id="CD009669-sec-0110"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0111"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included abnormal blood loss, bradycardia, hypertension, junctional rhythm, kidney failure, premature atrial and ventricular contractions and ST elevation (<a href="#CD009669-tbl-0013">Table 2</a>). Dopexamine showed a slightly better safety profile compared to dopamine. </p> </section> </section> <section id="CD009669-sec-0112"> <h4 class="title">6. Milrinone versus dobutamine</h4> <p>There was only one small, multicentre study with 120 participants investigating milrinone compared with dobutamine in the context of cardiac surgery complicated by LCOS (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>) (<a href="./full#CD009669-tbl-0006">summary of findings Table 6</a>). </p> <section id="CD009669-sec-0113"> <h5 class="title">All‐cause mortality</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0114"> <h5 class="title">MACE</h5> <p>The study authors claimed that there were no MACE in either intervention arm.</p> </section> <section id="CD009669-sec-0115"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0116"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0117"> <h5 class="title">Haemodynamics</h5> <p>The reported CI, PCWP and MAP showed no differences between participants randomised to milrinone and dobutamine (CI: 2.4 ± 0.77 versus 2.7 ± 2.32; PCWP: 11.2 ± 3.09 versus 12.6 ± 5.42; MAP: 68.5 ± 21.68 versus 75.5 ± 32.53) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0030" title="">Analysis 6.1</a>; <a href="./references#CD009669-fig-0031" title="">Analysis 6.2</a>; <a href="./references#CD009669-fig-0032" title="">Analysis 6.3</a>). </p> </section> <section id="CD009669-sec-0118"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0119"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included atrial fibrillation, bradycardia, haemorrhage, hypertension, hypotension, oligouria and tachycardia (<a href="#CD009669-tbl-0013">Table 2</a>). No intervention group was superior with regard to the safety profile. </p> </section> </section> <section id="CD009669-sec-0120"> <h4 class="title">7. Enoximone versus dobutamine</h4> <p>There were three small, single‐centre trials with 77 participants investigating enoximone compared with dobutamine in the context of acute HF (<a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>) or cardiac surgery (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>) complicated by LCOS/CS (<a href="./full#CD009669-tbl-0007">summary of findings Table 7</a>). </p> <section id="CD009669-sec-0121"> <h5 class="title">All‐cause mortality</h5> <p>Information on mortality was restricted to one study (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>). </p> <section id="CD009669-sec-0122"> <h6 class="title">Short‐term</h6> <p>We are uncertain about the effects on short‐term mortality with no deaths out of 18 participants in the intervention arm with enoximone compared with two deaths out of 19 participants (10.5%) in the control group treated with dobutamine (RR 0.21; 95% CI 0.01 to 4.11; participants = 37; studies = 1; very low‐quality evidence). Since there were no events in the intervention group, the anticipated absolute effects were not reliably estimable (<a href="./references#CD009669-fig-0033" title="">Analysis 7.1</a>; <a href="./references#CD009669-fig-0034" title="">Analysis 7.2</a>). </p> </section> <section id="CD009669-sec-0123"> <h6 class="title">Long‐term</h6> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0124"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses. </p> </section> </section> <section id="CD009669-sec-0125"> <h5 class="title">MACE</h5> <p>In <a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>, the study authors claimed that there were no MACE in either intervention arm. No results were available from <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a> and <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>. </p> </section> <section id="CD009669-sec-0126"> <h5 class="title">Length of hospital stay</h5> <p>Information on length of hospital stay was restricted to one study (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>). A shorter stay in the ICU was reported in the enoximone group compared to the dobutamine group, with high imprecision in particular in the dobutamine intervention arm (92 ± 37 h compared to 155 ± 129 h). </p> </section> <section id="CD009669-sec-0127"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0128"> <h5 class="title">Haemodynamics</h5> <p>Information on haemodynamics was restricted to two studies (<a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>) with missing information on MAP in <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>. The reported CI and PCWP showed no differences between participants randomised to enoximone and dobutamine (<a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>: CI: 2.56 ± 0.74 versus 2.80 ± 0.35; PCWP: 20.0 ± 5.7 versus 23.7 ± 6.6; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>: CI: 2.8 ± 0.6 versus 3.1 ± 0.9; PCWP: 13.1 ± 4.2 versus 12.8 ± 4.1) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0035" title="">Analysis 7.3</a>; <a href="./references#CD009669-fig-0036" title="">Analysis 7.4</a>). Small differences were found by <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a> in MAP (78 ± 11 versus 93 ± 17) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0037" title="">Analysis 7.5</a>). </p> </section> <section id="CD009669-sec-0129"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0130"> <h5 class="title">Adverse events</h5> <p>Information on adverse events was restricted to two studies (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>). Reported adverse events included haemorrhage, hepatic cytolysis, thrombocytopenia, tachycardia and/or hypertension and ventricular hyperexcitability (<a href="#CD009669-tbl-0013">Table 2</a>). No intervention group was superior with regard to the safety profile. </p> </section> </section> <section id="CD009669-sec-0131"> <h4 class="title">8. Epinephrine versus norepinephrine</h4> <p>There was only one small, multicentre study with 57 participants investigating epinephrine compared with norepinephrine in the context of CS complicating AMI (<a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>) (<a href="./full#CD009669-tbl-0008">summary of findings Table 8</a>). </p> <section id="CD009669-sec-0132"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0133"> <h6 class="title">Short‐term</h6> <p>We are uncertain about the effects on short‐term mortality with 13 deaths out of 27 participants (48.1%) in the intervention arm with epinephrine compared with eight deaths out of 30 participants (26.7%) in the control group treated with norepinephrine (RR 1.81, 0.89 to 3.68; participants = 57; studies = 1; very low‐quality evidence). Out of 1000 people, approximately 266 would be expected to die with standard cardiac care with norepinephrine within a short‐term follow‐up period compared to 482 (95% CI 237 to 979) with epinephrine (<a href="./references#CD009669-fig-0038" title="">Analysis 8.1</a>; <a href="./references#CD009669-fig-0039" title="">Analysis 8.2</a>). </p> </section> <section id="CD009669-sec-0134"> <h6 class="title">Long‐term</h6> <p>We are uncertain about the effects on long‐term mortality with 14 deaths out of 27 participants (51.9%) in the intervention arm with epinephrine compared with 11 deaths out of 30 participants (36.7%) in the control group treated with norepinephrine (RR 1.41, 0.78 to 2.56; participants = 57; studies = 1; very low‐quality evidence). Out of 1000 people, approximately 366 would be expected to die with standard cardiac care with norepinephrine within a long‐term follow‐up period compared to 516 (95% CI 285 to 937) with epinephrine (<a href="./references#CD009669-fig-0040" title="">Analysis 8.3</a>; <a href="./references#CD009669-fig-0041" title="">Analysis 8.4</a>) </p> </section> <section id="CD009669-sec-0135"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses.. </p> </section> </section> <section id="CD009669-sec-0136"> <h5 class="title">MACE</h5> <p>The study authors claimed that there were no MACE in either intervention arm.</p> </section> <section id="CD009669-sec-0137"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0138"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0139"> <h5 class="title">Haemodynamics</h5> <p>The reported CI showed no differences between participants randomised to epinephrine or norepinephrine (median CI 2.6 L/min/m<sup>2</sup> in both groups; IQR 1.9 to 3.3 on epinephrine versus 2.2 to 3.2 on norepinephrine) (<a href="#CD009669-tbl-0012">Table 1</a>). Small differences were found in PCWP and MAP (PCWP: 12.5 ± 4.1 versus 15.8 ± 5.7; MAP: 83.7 ± 12.3 versus 76.5 ± 8.1) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0042" title="">Analysis 8.5</a>; <a href="./references#CD009669-fig-0043" title="">Analysis 8.6</a>). </p> </section> <section id="CD009669-sec-0140"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0141"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included arrhythmia, need for extracorporeal life support and refractory shock (<a href="#CD009669-tbl-0013">Table 2</a>). Norepinephrine showed a slightly better safety profile compared to epinephrine. </p> </section> </section> <section id="CD009669-sec-0142"> <h4 class="title">9. Dopamine‐milrinone versus dopamine‐dobutamine</h4> <p>There was only one small, single‐centre study with 20 participants investigating dopamine‐milrinone compared with dopamine‐dobutamine in the context of CS complicating acute HF (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>) (<a href="./full#CD009669-tbl-0009">summary of findings Table 9</a>). </p> <section id="CD009669-sec-0143"> <h5 class="title">All‐cause mortality</h5> <section id="CD009669-sec-0144"> <h6 class="title">Short‐term</h6> <p>We are uncertain about the effects on ICU mortality with four deaths out of 10 participants in either intervention arm (40%) (RR 1.0; 95% CI 0.34 to 2.93; participants = 20; studies = 1; very low‐quality evidence). Out of 1000 people, approximately 400 per 1000 would be expected to die with standard cardiac care with dopamine‐dobutamine within ICU compared to 400 (95% CI 136 to 1172) with dopamine‐milrinone (<a href="./references#CD009669-fig-0044" title="">Analysis 9.1</a>; <a href="./references#CD009669-fig-0045" title="">Analysis 9.2</a>). </p> </section> <section id="CD009669-sec-0145"> <h6 class="title">Long‐term</h6> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0146"> <h6 class="title">Subgroup and sensitivity analyses</h6> <p>Subgroup and sensitivity analyses were not applicable on the basis of this one trial without internally reported subgroup analyses. </p> </section> </section> <section id="CD009669-sec-0147"> <h5 class="title">MACE</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0148"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0149"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0150"> <h5 class="title">Haemodynamics</h5> <p>The reported CI, PCWP and MAP showed no differences between participants randomised to dopamine‐milrinone and dopamine‐dobutamine (CI: 2.6 ± 0.31 versus 2.9 ± 0.63; PCWP: 17 ± 4.42 versus 19 ± 6.32; MAP: 65 ± 7.9 versus 71 ± 12.01) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0046" title="">Analysis 9.3</a>; <a href="./references#CD009669-fig-0047" title="">Analysis 9.4</a>; <a href="./references#CD009669-fig-0048" title="">Analysis 9.5</a>). </p> </section> <section id="CD009669-sec-0151"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0152"> <h5 class="title">Adverse events</h5> <p>No results were available from the included study.</p> </section> </section> <section id="CD009669-sec-0153"> <h4 class="title">10. Enoximone versus piroximone</h4> <p>There was only one small, single‐centre study with 20 participants investigating enoximone compared with piroximone in the context of cardiac surgery complicated by LCOS (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>) (<a href="./full#CD009669-tbl-0010">summary of findings Table 10</a>). </p> <section id="CD009669-sec-0154"> <h5 class="title">All‐cause mortality</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0155"> <h5 class="title">MACE</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0156"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0157"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0158"> <h5 class="title">Haemodynamics</h5> <p>The reported CI, PCWP and MAP showed no differences between participants randomised to enoximone and piroximone (CI: 2.4 ± 0.5 versus 2.5 ± 0.4; PCWP: 8.5 ± 2.0 versus 9.2 ± 1.9; MAP: 72.9 ± 8.7 versus 69.6 ± 7.0) (<a href="#CD009669-tbl-0012">Table 1</a>; <a href="./references#CD009669-fig-0049" title="">Analysis 10.1</a>; <a href="./references#CD009669-fig-0050" title="">Analysis 10.2</a>; <a href="./references#CD009669-fig-0051" title="">Analysis 10.3</a>). </p> </section> <section id="CD009669-sec-0159"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0160"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included arrhythmia and hypotension (<a href="#CD009669-tbl-0013">Table 2</a>). No intervention group was superior with regard to the safety profile. </p> </section> </section> <section id="CD009669-sec-0161"> <h4 class="title">11. Enoximone versus epinephrine‐nitroglycerine</h4> <p>There was only one small, single‐centre study with 12 participants investigating enoximone compared with epinephrine‐nitroglycerine in the context of cardiac surgery complicated by LCOS (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>) (<a href="./full#CD009669-tbl-0011">summary of findings Table 11</a>). </p> <section id="CD009669-sec-0162"> <h5 class="title">All‐cause mortality</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0163"> <h5 class="title">MACE</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0164"> <h5 class="title">Length of hospital stay</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0165"> <h5 class="title">Quality of life</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0166"> <h5 class="title">Haemodynamics</h5> <p>The study authors claimed that there were no treatment‐related differences.</p> </section> <section id="CD009669-sec-0167"> <h5 class="title">Costs</h5> <p>No results were available from the included study.</p> </section> <section id="CD009669-sec-0168"> <h5 class="title">Adverse events</h5> <p>Reported adverse events included arrhythmia and tachycardia (<a href="#CD009669-tbl-0013">Table 2</a>). No events were reported in either intervention group. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009669-sec-0169" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009669-sec-0169"></div> <p>This systematic review included 19 RCTs that analysed 2385 participants in trials with greatly differing mortality rates of between 0% and 47%. </p> <section id="CD009669-sec-0170"> <h3 class="title" id="CD009669-sec-0170">Summary of main results</h3> <section id="CD009669-sec-0171"> <h4 class="title">Drugs examined</h4> <p>Nine studies investigated levosimendan and compared its efficacy and safety with standard cardiac care plus dobutamine, enoximone or placebo. Five trials investigated enoximone and compared its efficacy and safety with standard cardiac care plus dobutamine, piroximone or epinephrine‐nitroglycerine. Two trials investigated epinephrine in comparison to either norepinephrine or the combination of norepinephrine and dobutamine. Single trials compared dopexamine to dopamine, milrinone to dobutamine or the combination of dopamine and milrinone to the combined use of dopamine and dobutamine. </p> </section> <section id="CD009669-sec-0172"> <h4 class="title">Endpoints</h4> <p>Thirteen studies reported mortality outcomes, while length of ICU and intra‐hospital stay were reported in three trials only. Haemodynamic parameters (surrogate markers for morbidity) were available in 15 trials and MACE/adverse events were reported in 16 studies. No data were available for quality of life or medical costs in any trial. </p> </section> <section id="CD009669-sec-0173"> <h4 class="title">Mortality</h4> <p>Levosimendan compared to dobutamine may reduce all‐cause mortality in the short term but may make little or no difference in the long term (low‐quality evidence) (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>). Very low‐quality evidence shows uncertainty around the effect of levosimendan versus placebo (long‐term data; no short‐term data available) (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>); levosimendan versus enoximone (short‐term data; no long‐term data available) (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>); epinephrine versus norepinephrine‐dobutamine (short‐term data; no long‐term data available) (<a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>); dopexamine versus dopamine (no deaths occurred in the short‐term; no long‐term data available) (<a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a>); enoximone versus dobutamine (short‐term data; no long‐term data available) (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>); and epinephrine versus norepinephrine (short‐term and long‐term data) (<a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>). The study investigating the comparison of dopamine‐milrinone with dopamine‐dobutamine (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>) was restricted to short‐term mortality and presented no differences in the intra‐hospital period with very low‐quality evidence. No data were available to address the effect of milrinone compared to dobutamine (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>) and of enoximone compared to either piroximone (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>) or epinephrine‐nitroglycerine (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). </p> </section> <section id="CD009669-sec-0174"> <h4 class="title">Length of ICU and intra‐hospital stay</h4> <p>Only three of the 19 trials reported length of ICU stay (<a href="http://Atallah 1990" target="_blank">Atallah 1990</a>; <a href="http://Fuhrmann 2008" target="_blank">Fuhrmann 2008</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>). <a href="http://Levin 2008" target="_blank">Levin 2008</a> indicated that participants had a shorter time in the ICU with levosimendan compared to dobutamine, <a href="http://Fuhrmann 2008" target="_blank">Fuhrmann 2008</a> with levosimendan compared to enoximone and <a href="http://Atallah 1990" target="_blank">Atallah 1990</a> with enoximone compared to dobutamine. In all of these studies, the results of comparison groups indicated a high level of uncertainty. There were no data concerning intra‐hospital stay. </p> </section> <section id="CD009669-sec-0175"> <h4 class="title">Haemodynamics</h4> <p>Some beneficial effects on certain haemodynamic variables (CI, PCWP, MAP) were reported for levosimendan in comparison to dobutamine (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>), enoximone (<a href="http://Fuhrmann 2008" target="_blank">Fuhrmann 2008</a>) or placebo (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>); for epinephrine in comparison to norepinephrine (<a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>); as well as for dopexamine in comparison to dopamine (<a href="http://Rosseel 1997" target="_blank">Rosseel 1997</a>). No clinically relevant differences in CI, PCWP and MAP were reported for epinephrine compared to norepinephrine‐dobutamine (<a href="http://Levy 2011" target="_blank">Levy 2011</a>); for milrinone compared to dobutamine (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>); for dopamine‐milrinone compared to dopamine‐dobutamine (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>); as well as for enoximone compared to dobutamine (<a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>), piroximone (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>) or epinephrine‐nitroglycerine (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). </p> </section> <section id="CD009669-sec-0176"> <h4 class="title">Adverse events</h4> <p><a href="http://Levin 2008" target="_blank">Levin 2008</a> reported a better safety profile of levosimendan compared to dobutamine, but this observation was not found in the studies of <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> and <a href="http://Mebazaa 2007" target="_blank">Mebazaa 2007</a>. A slightly better safety profile was reported by <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> for levosimendan compared to enoximone; by <a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> for dopexamine compared to dopamine; by <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> for norepinephrine‐dobutamine compared to epinephrine; and by <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> for norepinephrine compared to epinephrine. No intervention group was superior with regard to the safety profile for the comparisons levosimendan versus placebo (<a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>), milrinone versus dobutamine (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>), enoximone versus epinephrine‐nitroglycerine (<a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>), as well as enoximone versus dobutamine (<a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>) or piroximone (<a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>). No data were available to address the comparison dopamine‐milrinone versus dopamine‐dobutamine (<a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>). </p> </section> <section id="CD009669-sec-0177"> <h4 class="title">Quality of life and costs</h4> <p>No data addressing quality of life and health care costs were available in any of these trials. </p> </section> </section> <section id="CD009669-sec-0178"> <h3 class="title" id="CD009669-sec-0178">Overall completeness and applicability of evidence</h3> <p>Data from the included studies were too limited to support therapeutic strategies on the basis of the derived evidence on the efficacy and safety of the investigated drugs. Furthermore, it must be noted that some of the included studies dated back many years. The resulting differences in the guidelines and clinical standards applicable at earlier times when studies were conducted (for example, with regard to myocardial revascularisation) may have had an influence on effects observed. This is not a judgement concerning the potential benefits of the investigated therapeutic strategies and does not rule out the possibility that larger RCTs might verify potential beneficial effects in the future. </p> </section> <section id="CD009669-sec-0179"> <h3 class="title" id="CD009669-sec-0179">Quality of the evidence</h3> <p>We identified a total of 19 eligible studies with 2385 participants and included these studies in 11 comparisons to current standard therapies. All these studies were published as full texts; eight of them were sponsored by manufacturers of the drugs (<a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="http://Husebye 2013" target="_blank">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a>; <a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>; <a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a>). In <a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a>, a conflict of interest statement was lacking. </p> <p>Effect estimates for our primary outcome, all‐cause mortality, are based on the results from one to six RCTs of small to moderate size. Due to the small number of eligible trials, the use of funnel plots for the graphical detection of publication bias was not possible since the power of the tests was too low to distinguish chance from real asymmetry. The mortality rates reported by <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="http://Atallah 1990" target="_blank">Atallah 1990</a>; <a href="http://Garc%CE%AFa-Gonz%C3%A1lez 2006" target="_blank">Garcίa-González 2006</a> and <a href="http://Rosseel 1997" target="_blank">Rosseel 1997</a> were surprisingly low and in marked contrast to the expected mortality rates of between 40% and 80%. The limited data available on haemodynamic parameters showed clinically relevant differences in CI at baseline in different studies. The heterogeneity in the baseline haemodynamic characteristics, however, raises concerns over the definitions of CS and LCOS used in these trials. This could also be an explanation for the differences in mortality rates. </p> <p>We downgraded the high‐quality evidence of eligible RCTs due to relevant imprecision, publication bias and study limitations (risk of bias). Quality of the evidence was downgraded for imprecision if the optimal information size criterion was not met and if clinical action would differ if the lower or the upper boundary of the CI represented the truth (<a href="./references#CD009669-bbs2-0047" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93.">Guyatt 2011b</a>). We downgraded the quality of the evidence for high probability of publication bias due to incomplete outcome data with exclusion of particular participants (<a href="./references#CD009669-bbs2-0051" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277-82.">Guyatt 2011f</a>). Downgrading took place with respect to high risk of performance and detection bias due to lack of blinding of participants, personnel and outcome assessment, methodological limitations from inappropriate random sequence generation or inappropriate administration of an intervention or stopping trial early for benefit (<a href="./references#CD009669-bbs2-0048" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407-15.">Guyatt 2011c</a>). </p> </section> <section id="CD009669-sec-0180"> <h3 class="title" id="CD009669-sec-0180">Potential biases in the review process</h3> <p>We contacted all authors of eligible trials requesting individual patient data. Considering that the total number of eligible studies and included participants was relatively small, bias could have been introduced merely by the fact that individual patient data were not provided. </p> <p>As CS is a haemodynamically defined state, it is of major concern if haemodynamic parameters were not available for all participants. As a result, inclusion criteria and definition of CS fully relied on the definition of CS originally required for study inclusion. For this reason, we cannot verify that all reported data were related to patients appropriately diagnosed with CS as it was defined in the SHOCK trial (<a href="./references#CD009669-bbs2-0058" title="HochmanJS , SleeperLA , WebbJG , SanbornTA , WhiteHD , TalleyJD , et al. Early revascularisation in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine1999;341:625-34.">Hochman 1999</a>). </p> <p>In all except one trial investigating levosimendan, the drug was started by an initial bolus. As the bolus of levosimendan might be associated with hypotensive side effects, we cannot rule out the possibility that the potentially beneficial effects of the drug might have been masked by the adverse effect of bolus application. </p> </section> <section id="CD009669-sec-0181"> <h3 class="title" id="CD009669-sec-0181">Agreements and disagreements with other studies or reviews</h3> <p>During recent decades, several randomised trials, cohort studies and systematic reviews have investigated inotropic drugs (in particular, levosimendan) studying patients with CS or LCOS. These original trials have been summarised in 14 systematic reviews and meta‐analyses (<a href="./references#CD009669-bbs2-0031" title="BellettiA , CastroML , SilvettiS , GrecoT , Biondi-ZoccaiG , PasinL , et al. The effect of inotropes and vasopressors on mortality. British Journal of Anaesthesia2015;115(5):656-75.">Belletti 2015</a>; <a href="./references#CD009669-bbs2-0036" title="DelaneyA , BradfordC , McCaffreyJ , BagshawSM , LeeR . Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International Journal of Cardiology2010;138:281-9.">Delaney 2010</a>; <a href="./references#CD009669-bbs2-0043" title="FangM , CaoH , WangZ . Levosimendan in patients with cardiogenic shock complicating myocardial infarction. Medicina Intensiva2018;42(7):409-15.">Fang 2018</a>;<a href="./references#CD009669-bbs2-0054" title="HarrisonRW , HasselbladV , MehtaRH , LevinR , HarringtonRA , AlexanderJH . Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2013;27(6):1224-32.">Harrison 2013</a>; <a href="./references#CD009669-bbs2-0062" title="HuangX , LeiS , ZhuM , JiangR , HuangL , XiaG , et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Journal of Zhejiang University - SCIENCE B2013;14(5):400-15.">Huang 2013</a>; <a href="./references#CD009669-bbs2-0064" title="KaramiM , HemradjVV , OuweneelDM , Den UilCA , LimpensJ , OtterspoorLC , et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: a systematic review and meta-analysis. Journal of Clinical Medicine2020;9(7):e2051.">Karami 2020</a>; <a href="./references#CD009669-bbs2-0065" title="KosterG , WetterslevJ , GluudC , ZijlstraJG , ScheerenTWL , Van der HorstICC , et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine2015;41:203-21.">Koster 2015</a>; <a href="./references#CD009669-bbs2-0066" title="LandoniG , MizziA , Biondi-ZoccaiG , BrunoG , BignamiE , CornoL , et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. Journal of Cardiothoracic and Vascular Anesthesia2010;24(1):51-7.">Landoni 2010a</a>; <a href="./references#CD009669-bbs2-0067" title="LandoniG , MizziA , Biondi-ZoccaiA , BignamiE , PratiP , AjelloV , et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiologica2010;76(4):276-86.">Landoni 2010b</a>; <a href="./references#CD009669-bbs2-0068" title="LandoniG , Biondi-ZoccaiG , GrecoM , GrecoT , BignamiE , MorelliA , et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Critical Care Medicine2012;40(2):634-46.">Landoni 2012</a>; <a href="./references#CD009669-bbs2-0070" title="LeopoldV , GayatE , PirracchioR , SpinarJ , ParenicaJ , TarvasmakiT , et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine2018;44(6):847-56.">Leopold 2018</a>;<a href="./references#CD009669-bbs2-0071" title="MaharajR , MetaxaV . Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Critical Care2011;15:R140.">Maharaj 2011</a>; <a href="./references#CD009669-bbs2-0082" title="RibeiroRA , RohdeLEP , PolanczykCA . Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arquivos Brasileiros de Cardiologia2010;95(2):230-7.">Ribeiro 2010</a>; <a href="./references#CD009669-bbs2-0092" title="ThackrayS , EasthaughJ , FreemantleN , ClelandJG . The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. European Journal of Heart Failure2002;4(4):515-29.">Thackray 2002</a>). </p> <p>Regarding levosimendan, no significant effects on mortality compared to control were described by <a href="./references#CD009669-bbs2-0031" title="BellettiA , CastroML , SilvettiS , GrecoT , Biondi-ZoccaiG , PasinL , et al. The effect of inotropes and vasopressors on mortality. British Journal of Anaesthesia2015;115(5):656-75.">Belletti 2015</a>; <a href="./references#CD009669-bbs2-0043" title="FangM , CaoH , WangZ . Levosimendan in patients with cardiogenic shock complicating myocardial infarction. Medicina Intensiva2018;42(7):409-15.">Fang 2018</a> and <a href="./references#CD009669-bbs2-0082" title="RibeiroRA , RohdeLEP , PolanczykCA . Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arquivos Brasileiros de Cardiologia2010;95(2):230-7.">Ribeiro 2010</a>. <a href="http://Belletti 2015" target="_blank">Belletti 2015</a> performed a meta‐analysis of randomised trials to investigate the effect of inotrope/vasopressor treatment on mortality of critically ill patients. The search was updated in April 2015. A total of 28,280 participants from 177 trials were summarised; three of those studies were also included in this review (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Husebye 2013" target="_blank">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). Pooled estimates showed no difference in mortality between the group receiving inotropes/vasopressors and the control group (RR 0.98, 95% CI 0.96 to 1.01) with low heterogeneity (I<sup>2</sup> = 6%). <a href="./references#CD009669-bbs2-0043" title="FangM , CaoH , WangZ . Levosimendan in patients with cardiogenic shock complicating myocardial infarction. Medicina Intensiva2018;42(7):409-15.">Fang 2018</a> evaluated whether levosimendan improved clinical outcome in patients with CS complicating AMI. That search, which was finalised in May 2016, combined 13 studies (both randomised and non‐randomised trials) comprising a total of 648 participants, which included three studies from this review (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> (secondary publication of <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>)). There was a non‐significant reduction in mortality with the use of levosimendan compared to the controls (RR 0.82, 95% CI 0.65 to 1.01) with no heterogeneity between the results of individual studies (I<sup>2</sup> = 0%). <a href="./references#CD009669-bbs2-0082" title="RibeiroRA , RohdeLEP , PolanczykCA . Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arquivos Brasileiros de Cardiologia2010;95(2):230-7.">Ribeiro 2010</a> analysed morbidity and mortality associated with levosimendan in the treatment of acutely decompensated HF. The search was set to an end date of July 2009 and included 19 randomised trials with 3719 participants. No significant reduction in relative risk for overall death was found for the comparison of levosimendan with placebo (seven trials enrolling 1652 participants, including one trial also being part of the present review (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>); RR 0.87, 95% CI 0.65 to 1.18) with low heterogeneity between the results of individual studies (I<sup>2</sup> = 12%). Likewise, the comparison of levosimendan with dobutamine supported no treatment option (10 trials enrolling 2067 participants, including five trials also being part of the present review (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>;<a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> (secondary publication of <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>)); RR 0.87, 95% CI 0.75 to 1.02) with no heterogeneity between the results of individual studies (I<sup>2</sup> = 0%). </p> <p>Differential results regarding the levosimendan effect, according to control group and subgroup analyses, were gained by <a href="./references#CD009669-bbs2-0036" title="DelaneyA , BradfordC , McCaffreyJ , BagshawSM , LeeR . Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International Journal of Cardiology2010;138:281-9.">Delaney 2010</a> and <a href="./references#CD009669-bbs2-0065" title="KosterG , WetterslevJ , GluudC , ZijlstraJG , ScheerenTWL , Van der HorstICC , et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine2015;41:203-21.">Koster 2015</a>. <a href="./references#CD009669-bbs2-0036" title="DelaneyA , BradfordC , McCaffreyJ , BagshawSM , LeeR . Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. International Journal of Cardiology2010;138:281-9.">Delaney 2010</a> described the efficacy and safety of levosimendan for the treatment of acute severe HF. The systematic search was finalised in June 2007. The meta‐analysis included 19 randomised trials with 3650 participants. Six studies with a total of 1578 participants, including one trial we also analysed in this review (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>), compared levosimendan with placebo. There was no significant reduction in mortality with levosimendan (OR 0.83, 95% CI 0.62 to 1.10) with low heterogeneity between the results of the individual trials (I<sup>2</sup> = 25.7%). Eight studies with a total of 1979 participants enrolled, including four trials also analysed in this review (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a>), compared levosimendan to dobutamine and reported a significant reduction in mortality after levosimendan therapy (OR 0.75, 95% CI 0.61 to 0.92) with moderate heterogeneity (I<sup>2</sup> = 44.6%). <a href="./references#CD009669-bbs2-0065" title="KosterG , WetterslevJ , GluudC , ZijlstraJG , ScheerenTWL , Van der HorstICC , et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine2015;41:203-21.">Koster 2015</a> assessed the benefit and harm of levosimendan in critically ill patients suffering from LCOS. The electronic literature search strategy was last updated in February 2014 and included 49 randomised trials overseeing a total of 6688 participants. Nine of these studies are also part of the present review (<a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a>; <a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>; <a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>; <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a>;<a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). Pooled analysis of the studies on critically ill participants without cardiac surgery compared to varying controls showed an association between levosimendan and mortality (RR 0.83, 95% CI 0.59 to 0.97). Likewise, pooled analysis of all trials, including cardiac surgery participants, showed an association between levosimendan and mortality (RR 0.52, 95% CI 0.37 to 0.73). However, subgroup analyses showed that the association between levosimendan therapy and mortality could not be confirmed if only studies with a low risk of bias were considered (participants without cardiac surgery: RR 0.83, 95% CI 0.48 to 1.55; cardiac surgery participants RR 1.02, 95% CI 0.48 to 2.16). </p> <p>Significant effects of levosimendan compared to control were reported by <a href="./references#CD009669-bbs2-0054" title="HarrisonRW , HasselbladV , MehtaRH , LevinR , HarringtonRA , AlexanderJH . Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2013;27(6):1224-32.">Harrison 2013</a>; <a href="./references#CD009669-bbs2-0062" title="HuangX , LeiS , ZhuM , JiangR , HuangL , XiaG , et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Journal of Zhejiang University - SCIENCE B2013;14(5):400-15.">Huang 2013</a>; <a href="./references#CD009669-bbs2-0066" title="LandoniG , MizziA , Biondi-ZoccaiG , BrunoG , BignamiE , CornoL , et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. Journal of Cardiothoracic and Vascular Anesthesia2010;24(1):51-7.">Landoni 2010a</a>; <a href="./references#CD009669-bbs2-0067" title="LandoniG , MizziA , Biondi-ZoccaiA , BignamiE , PratiP , AjelloV , et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiologica2010;76(4):276-86.">Landoni 2010b</a>; <a href="./references#CD009669-bbs2-0068" title="LandoniG , Biondi-ZoccaiG , GrecoM , GrecoT , BignamiE , MorelliA , et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Critical Care Medicine2012;40(2):634-46.">Landoni 2012</a> and <a href="./references#CD009669-bbs2-0071" title="MaharajR , MetaxaV . Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Critical Care2011;15:R140.">Maharaj 2011</a>. <a href="http://Harrison 2013" target="_blank">Harrison 2013</a> performed a meta‐analysis investigating the effects of levosimendan in cardiac surgery with and without preexisting systolic dysfunction prior to the procedure in 14 randomised trials enrolling a total of 1155 participants. The timing of levosimendan treatment varied between preoperative to intraoperative and postoperative phases. The search was finalised in May 2012 with one study of this review being incorporated (<a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>). Pooled results demonstrated a significant reduction in mortality with levosimendan (risk difference ‐4.2%, 95% CI ‐7.2% to ‐1.1%) and low heterogeneity (I<sup>2</sup> = 28%), which was not significantly affected by the timing of levosimendan administration or the type of control (either placebo or dobutamine or milrinone or IABP). Subgroup analysis showed that the benefit associated with levosimendan was restricted to studies investigating participants with reduced ejection fraction (mean ejection fraction &lt; 40%). This condition does not apply to participants studied in the trial performed by <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>. <a href="./references#CD009669-bbs2-0062" title="HuangX , LeiS , ZhuM , JiangR , HuangL , XiaG , et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. Journal of Zhejiang University - SCIENCE B2013;14(5):400-15.">Huang 2013</a> analysed the clinical efficacy of levosimendan versus dobutamine in any setting in critically ill participants. The search was finalised in February 2012 and included 22 randomised trials with a total of 3052 participants. Six trials of the present review were included as well (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>; <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a>;<a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> (secondary publication of <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>)). Compared with dobutamine, levosimendan was found to be associated with a significant reduction in mortality (RR 0.81, 95% CI 0.70 to 0.92). The heterogeneity between the results of individual studies was small (I<sup>2</sup> = 6%). According to the reported subgroup analyses, benefit from levosimendan was present in participants undergoing cardiac surgery, ischaemic HF and concomitant beta‐blocker therapy, but not in hypotensive participants or in the case of (supra‐)ventricular arrhythmias. The studies by <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a> and <a href="http://Levin 2008" target="_blank">Levin 2008</a> were included in the cardiac surgery setting; the studies by <a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>, <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a> and <a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> were included in the cardiology setting. <a href="./references#CD009669-bbs2-0066" title="LandoniG , MizziA , Biondi-ZoccaiG , BrunoG , BignamiE , CornoL , et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. Journal of Cardiothoracic and Vascular Anesthesia2010;24(1):51-7.">Landoni 2010a</a> studied whether levosimendan was associated with improved survival in people undergoing cardiac surgery. The search was updated in January 2009 and identified 10 randomised trials with 440 participants including two studies being part of this review (<a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>). Levosimendan led to a significant reduction in postoperative mortality compared to control (either placebo or dobutamine or milrinone) with OR 0.35 (95% CI 0.18 to 0.71) with low heterogeneity (I<sup>2</sup> = 27.4%). <a href="./references#CD009669-bbs2-0067" title="LandoniG , MizziA , Biondi-ZoccaiA , BignamiE , PratiP , AjelloV , et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiologica2010;76(4):276-86.">Landoni 2010b</a> also investigated the impact of levosimendan on mortality in critically ill participants of variable origin. The systematic search was updated in November 2008 identifying 27 randomised trials comparing levosimendan versus control with a total of 3350 participants, also including seven studies included in this review (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>; <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a>;<a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> (secondary publication of <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>); <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>). Levosimendan was associated with a significant reduction in mortality (OR 0.74, 95% CI 0.62 to 0.89) with low heterogeneity between the results of individual studies (I<sup>2</sup> = 11.3%) as well as an increase in the rate of hypotension (OR 1.38; 95% CI 1.06 to 1.80) with moderate heterogeneity (I<sup>2</sup> = 37.7%). <a href="http://Landoni 2012" target="_blank">Landoni 2012</a> further updated a meta‐analysis of all RCTs on levosimendan to reach a definite conclusion of its role in participants requiring inotropic drugs. The search was updated in November 2010 and identified 45 randomised trials with 5480 participants. Levosimendan was associated with a significant reduction in mortality (RR 0.80, 95% CI 0.72 to 0.89) and low heterogeneity between study results (I<sup>2</sup> = 15.4%). This result was confirmed in studies with different control groups and in different settings. Six studies included in this review (<a href="http://Adamopoulos 2006" target="_blank">Adamopoulos 2006</a>; <a href="http://Follath (LIDO) 2002" target="_blank">Follath (LIDO) 2002</a>; <a href="http://Fuhrmann 2008" target="_blank">Fuhrmann 2008</a>; <a href="http://Garc%CE%AFa-Gonz%C3%A1lez 2006" target="_blank">Garcίa-González 2006</a>; <a href="http://Mebazaa (SURVIVE) 2007" target="_blank">Mebazaa (SURVIVE) 2007</a>;<a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a>) were in the subgroup designated 'cardiology', where a similar reduction of mortality was confirmed (RR 0.75, 95% CI 0.63 to 0.91) with low heterogeneity (I<sup>2</sup> = 25.5%). Two studies included in this review (<a href="http://Alvarez 2006" target="_blank">Alvarez 2006</a>; <a href="http://Levin 2008" target="_blank">Levin 2008</a>) were in the subgroup designated 'cardiac surgery', where the reduction in mortality was confirmed as well (RR 0.52, 95% CI 0.35 to 0.76) with no heterogeneity between the results of individual studies (I<sup>2</sup> = 0%). <a href="./references#CD009669-bbs2-0071" title="MaharajR , MetaxaV . Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Critical Care2011;15:R140.">Maharaj 2011</a> evaluated the effect of levosimendan versus control on mortality after coronary revascularisation. This systematic review was based on a search period up to August 2010 and included 17 randomised trials involving 729 participants. Levosimendan was associated with a reduced mortality after coronary revascularisation (OR 0.40, 95% CI 0.21 to 0.76) with low heterogeneity of study results (I<sup>2</sup> = 12%). Elective revascularisation showed a significant benefit (OR 0.36, 95% CI 0.18 to 0.72) over acute revascularisation (OR 0.61, 95% CI 0.19 to 1.89). The electively revascularised group included two studies (<a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>; <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>) and the acutely revascularised group included two further studies also included in this review (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>;<a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a> (secondary publication of <a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a>)). </p> <p>Only three meta‐analyses deal with inotropics other than levosimendan. <a href="http://Leopold 2018" target="_blank">Leopold 2018</a> evaluated the association between epinephrine use and short‐term mortality in all‐cause CS participants. The meta‐analysis was based on a search finalised in November 2017 and included 14 published cohorts and two unpublished data sets involving 2583 participants including one study also included in this review (<a href="http://Levy 2018" target="_blank">Levy 2018</a>). A positive correlation was found between percentages of epinephrine use and short‐term mortality (OR 3.3, 95% CI 2.8 to 3.9). <a href="./references#CD009669-bbs2-0092" title="ThackrayS , EasthaughJ , FreemantleN , ClelandJG . The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. European Journal of Heart Failure2002;4(4):515-29.">Thackray 2002</a> systematically reviewed the use of inotropic drugs acting through the adrenergic pathway in people with HF. In total, 21 randomised trials involving 632 participants were analysed including three studies comprising 75 participants comparing dobutamine with enoximone, of which two trials were also included in this review (<a href="http://Atallah 1990" target="_blank">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>). No differences in mortality were identified between dobutamine and alternative inotropic agents (OR 1.37, 95 % CI 0.23 to 8.46). <a href="./references#CD009669-bbs2-0064" title="KaramiM , HemradjVV , OuweneelDM , Den UilCA , LimpensJ , OtterspoorLC , et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: a systematic review and meta-analysis. Journal of Clinical Medicine2020;9(7):e2051.">Karami 2020</a> investigated the effect of vasopressors and inotropes (i.e. adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine, dopamine) on mortality in AMI‐related CS including both randomised and observational studies. The meta‐analysis was conducted on the basis of a search finalised in February 2019 comprising 19 studies (six RCTs, 13 prospective or retrospective cohorts) and 2478 participants including four studies also included in this review (<a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a>; <a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>; <a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>; <a href="./references#CD009669-bbs2-0085" title="Samimi-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127(2):284-7.">Samimi‐Fard 2008</a>). No association in mortality between therapy and control group was found; however, there was a trend toward better outcome in short‐term mortality with levosimendan compared to control (RR 0.69, 95% CI 0.47 to 1.00; I<sup>2</sup> = 39%). </p> <p>In conclusion, while some of the studies included in this review have been considered in published reviews, our systematic review differs from previously published reviews for several major reasons. This review: </p> <p> <ul id="CD009669-list-0019"> <li> <p>focusses on patients with AMI, HF or cardiac surgery complicated by CS or LCOS;</p> </li> <li> <p>excludes studies with prophylactic use of inotropic drugs in the context of cardiac surgery; </p> </li> <li> <p>is based on a previously published protocol as recommended by <a href="./references#CD009669-bbs2-0088" title="SheaBJ , HamelC , WellsGA , BouterLM , KristjanssonE , GrimshawJ , et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology2009;62(10):1013-20.">Shea 2009</a>; </p> </li> <li> <p>constitutes the most up‐to‐date literature review (as of October 2019);</p> </li> <li> <p>is not restricted to levosimendan and more broadly investigates different inotropic drugs including enoximone, piroximone, epinephrine, norepinephrine, dopexamine, milrinone, dopamine and dobutamine. </p> </li> </ul> </p> <p>This systematic review focusses on CS and LCOS in the acute setting. Trials on stable outpatient collectives discussed by <a href="./references#CD009669-bbs2-0075" title="NieminenMS , AltenbergerJ , Ben-GalT , BoehmerA , Comin-ColetJ , DicksteinK , et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure. International Journal of Cardiology2014;174(2):360-7.">Nieminen 2014</a> and <a href="./references#CD009669-bbs2-0089" title="SilvettiS , GrecoT , Di PrimaAL , MucchettiM , Lurdes CastroM , PasinL , et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients. Clinical Research in Cardiology2014;103(7):505-13.">Silvetti 2014</a> are not within the scope of this meta‐analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009669-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009669-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009669-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD009669-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 1: All‐cause short‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 3: All‐cause long‐term mortality" data-id="CD009669-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 3: All‐cause long‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 4: All‐cause long‐term mortality: sensitivity analysis" data-id="CD009669-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 4: All‐cause long‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 5: MACE (Perioperative infarction)" data-id="CD009669-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 5: MACE (Perioperative infarction)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 6: MACE (Cerebrovascular accidents)" data-id="CD009669-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 6: MACE (Cerebrovascular accidents)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 7: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 7: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 8: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 8: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Levosimendan versus dobutamine, Outcome 9: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Levosimendan versus dobutamine, Outcome 9: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Levosimendan versus placebo, Outcome 1: All‐cause long‐term mortality" data-id="CD009669-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Levosimendan versus placebo, Outcome 1: All‐cause long‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Levosimendan versus placebo, Outcome 2: All‐cause long‐term mortality: sensitivity analysis" data-id="CD009669-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Levosimendan versus placebo, Outcome 2: All‐cause long‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Levosimendan versus placebo, Outcome 3: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Levosimendan versus placebo, Outcome 3: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Levosimendan versus placebo, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Levosimendan versus placebo, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Levosimendan versus placebo, Outcome 5: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Levosimendan versus placebo, Outcome 5: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Levosimendan versus enoximone, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Levosimendan versus enoximone, Outcome 1: All‐cause short‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Levosimendan versus enoximone, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Levosimendan versus enoximone, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Levosimendan versus enoximone, Outcome 3: MACE (Cerebrovascular accidents)" data-id="CD009669-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Levosimendan versus enoximone, Outcome 3: MACE (Cerebrovascular accidents)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 1: All‐cause short‐term mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 3: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 3: Haemodynamics (Cardiac index) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Epinephrine versus norepinephrine‐dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopexamine versus dopamine, Outcome 1: MACE (Perioperative infarctions)" data-id="CD009669-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Dopexamine versus dopamine, Outcome 1: MACE (Perioperative infarctions)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopexamine versus dopamine, Outcome 2: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Dopexamine versus dopamine, Outcome 2: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopexamine versus dopamine, Outcome 3: Hemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Dopexamine versus dopamine, Outcome 3: Hemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopexamine versus dopamine, Outcome 4: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Dopexamine versus dopamine, Outcome 4: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Milrinone versus dobutamine, Outcome 1: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Milrinone versus dobutamine, Outcome 1: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Milrinone versus dobutamine, Outcome 2: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Milrinone versus dobutamine, Outcome 2: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Milrinone versus dobutamine, Outcome 3: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Milrinone versus dobutamine, Outcome 3: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enoximone versus dobutamine, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Enoximone versus dobutamine, Outcome 1: All‐cause short‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enoximone versus dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Enoximone versus dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enoximone versus dobutamine, Outcome 3: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Enoximone versus dobutamine, Outcome 3: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enoximone versus dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Enoximone versus dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Enoximone versus dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Enoximone versus dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 1: All‐cause short‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 3: All‐cause long‐term mortality" data-id="CD009669-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 3: All‐cause long‐term mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 4: All‐cause long‐term mortality: sensitivity analysis" data-id="CD009669-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 4: All‐cause long‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 5: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 5: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Epinephrine versus norepinephrine, Outcome 6: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Epinephrine versus norepinephrine, Outcome 6: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 1: All‐cause short‐term mortality" data-id="CD009669-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 1: All‐cause short‐term mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis" data-id="CD009669-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 2: All‐cause short‐term mortality: sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 3: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 3: Haemodynamics (Cardiac index) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 4: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Dopamine‐milrinone versus dopamine‐dobutamine, Outcome 5: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Enoximone versus piroximone, Outcome 1: Haemodynamics (Cardiac index)" data-id="CD009669-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Enoximone versus piroximone, Outcome 1: Haemodynamics (Cardiac index)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Enoximone versus piroximone, Outcome 2: Haemodynamics (Pulmonary capillary wedge pressure)" data-id="CD009669-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Enoximone versus piroximone, Outcome 2: Haemodynamics (Pulmonary capillary wedge pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009669-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/urn:x-wiley:14651858:media:CD009669:CD009669-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Enoximone versus piroximone, Outcome 3: Haemodynamics (Mean arterial pressure)" data-id="CD009669-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_t/tCD009669-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Enoximone versus piroximone, Outcome 3: Haemodynamics (Mean arterial pressure) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/media/CDSR/CD009669/image_n/nCD009669-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cardiogenic shock or low cardiac output syndrome<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> levosimendan<br/><b>Comparison</b>: dobutamine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>dobutamine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with</b> </p> <p><b>levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> range 15 to 31 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(53 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> (0.36 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1701<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to cardiac surgery or HF.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> range 4 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>242 per 1000</b><br/>(181 to 325) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> <br/>(0.63 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1591<br/>(4 studies)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to HF or AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in included studies with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met and 1 level for study limitation due to stopping trial early for benefit and methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to dobutamine for cardiogenic shock or low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo for cardiogenic shock or low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared with placebo for cardiogenic shock or low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock or low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> levosimendan </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause short‐term mortality:</b> 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> range 4 to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b><br/>(35 to 407) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> (0.16 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies included participants with LCOS or CS due to HF or AMI.</p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="0" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in included studies with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo for cardiogenic shock or low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Levosimendan compared to enoximone for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levosimendan compared with enoximone for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> levosimendan </p> <p><b>Comparison:</b> enoximone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause short‐term mortality:</b> 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> <p>(138 to 712)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> (0.22 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock.<br/><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met and 2 levels for study limitation due to stopping trial early for benefit and methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Levosimendan compared to enoximone for cardiogenic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Epinephrine compared to norepinephrine‐dobutamine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine‐dobutamine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention</b>: epinephrine </p> <p><b>Comparison</b>: norepinephrine‐dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with norepinephrine‐dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/>(109 to 1003) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> (0.41 to 3.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to HF.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm, and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Epinephrine compared to norepinephrine‐dobutamine for cardiogenic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Dopexamine compared to dopamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopexamine compared with dopamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> dopexamine </p> <p><b>Comparison:</b> dopamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopexamine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> time in hospital </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR not estimable<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with LCOS following elective surgery for CABG.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CABG:</b> coronary artery bypass graft surgery; <b>CI:</b> confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No in‐hospital deaths were observed in the study.<br/><sup>2</sup>Downgraded 1 level for imprecision due to optimal information size criterion not being met, 1 level for publication bias due to incomplete outcome data and 1 level for study limitation due to methodological limitations from inappropriate administration of an intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Dopexamine compared to dopamine for low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Milrinone compared to dobutamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Milrinone compared with dobutamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> milrinone </p> <p><b>Comparison:</b> dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with milrinone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Milrinone compared to dobutamine for low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enoximone compared to dobutamine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with dobutamine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> (0.01 to 4.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>very low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with LCOS after mitral valve surgery.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from a large observational study due to the small size of included studies in this population (<a href="./references#CD009669-bbs2-0090" title="SinghM , WhiteJ , HasdaiD , HodgsonPK , BergerPB , TopolEJ , et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock. Journal of the American College of Cardiology2007;50(18):1752–8.">Singh 2007</a>). </p> <p><sup>2</sup>No in‐hospital deaths were observed in the study.<br/><sup>3</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and 1 level for study limitation due to methodological limitations from lack of blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Enoximone compared to dobutamine for low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Epinephrine compared to norepinephrine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Epinephrine compared with norepinephrine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> epinephrine </p> <p><b>Comparison:</b> norepinephrine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with norepinephrine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> 28 days<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000<sup>1</sup><br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>482 per 1000</b> (237 to 979)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.81</b>  (0.89 to 3.68)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause long‐term mortality:</b> 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>516 per 1000</b><br/>(285 to 937) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.41 </b>  (0.78 to 2.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to AMI.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>AMI:</b> acute myocardial infarction; <b>CI:</b> Confidence interval; <b>CS:</b> cardiogenic shock; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to stopping trial early for benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Epinephrine compared to norepinephrine for cardiogenic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Dopamine‐milrinone compared to dopamine‐dobutamine for cardiogenic shock</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Dopamine‐milrinone compared with dopamine‐dobutamine for cardiogenic shock</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cardiogenic shock </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> dopamine‐milrinone </p> <p><b>Comparison:</b> dopamine‐dobutamine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine‐dobutamine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with dopamine‐milrinone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause short‐term mortality:</b> at intensive care unit </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b><br/>(136 to 1172) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.0</b> (0.34 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study included participants with CS due to HF.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause long‐term mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>CS:</b> cardiogenic shock; <b>HF:</b> heart failure; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control group risk estimate comes from the control group risk in a small included study with low cardiac output or cardiogenic shock. </p> <p><sup>2</sup>Downgraded 2 levels for imprecision due to optimal information size criterion not being met and confidence interval crossing line of null effect and including appreciable benefit and harm and 1 level for study limitation due to methodological limitations from lack of blinding and inappropriate random sequence generation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Dopamine‐milrinone compared to dopamine‐dobutamine for cardiogenic shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Enoximone compared to piroximone for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with piroximone for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> piroximone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with piroximone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Enoximone compared to piroximone for low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009669-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Enoximone compared to epinephrine‐nitroglycerine for low cardiac output syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Enoximone compared with epinephrine‐nitroglycerine for low cardiac output syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with low cardiac output syndrome </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> enoximone </p> <p><b>Comparison:</b> epinephrine‐nitroglycerine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with epinephrine‐nitroglycerine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with enoximone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not reported in any of the included studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Enoximone compared to epinephrine‐nitroglycerine for low cardiac output syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009669-tbl-0012"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Haemodynamics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Haemodynamics</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD (</b> 95% CI<b>)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention vs control</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>last measurements</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mean</b> ± <b>SD or median (IQR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>mean</b> ± <b>SD or median (IQR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Levosimendan versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 ± 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.11 to 0.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 ± 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.34 to 0.66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 ± 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 ± 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.65 to 0.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐6.77 to ‐1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.00 (‐8.07 to ‐3.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1 ± 1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.90 (‐3.43 to ‐2.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.0 ± 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐7.74 to ‐0.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.7 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.1 ± 4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.30 (‐3.21 to 0.61)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Levosimendan versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 ± 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.17 to 0.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (6 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9 ± 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.32 to 0.88)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0001" title="AdamopoulosS , ParissisJT , IliodromitisEK , ParaskevaidisI , TsiaprasD , FarmakisD , et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. American Journal of Cardiology2006;98:102-6. ">Adamopoulos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 ± 4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 (‐6.77 to ‐1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.0 ± 9.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.0 ± 6.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.0 (‐9.77 to ‐4.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.0 ± 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.0 ± 13.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.0 (‐9.54 to 1.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Levosimendan versus enoximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (48 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.5 ‐ 3.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.8 ‐ 3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (48 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.0 (16.0 ‐ 20.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 21.0 (19.0 ‐ 28.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (48 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.0 (58.0 ‐ 79.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.0 (63.0 ‐ 83.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Epinephrine versus norepinephrine‐dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (24 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 ± 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10 (‐0.22 to 0.42)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.0 ± 7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐5.01 to 5.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (24 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.0 ± 9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0 ± 11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.0 (‐8.19 to 6.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dopexamine versus dopamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (6 h after treatment initiation; L/min/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (0.02 to 0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.50 (‐2.93 to ‐0.07)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (6 h after treatment initiation; mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.3 ± 11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2 ± 12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.90 (‐7.60 to 3.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Milrinone versus dobutamine</b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (4 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 ± 0.77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 ± 2.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.92 to 0.32) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (4 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2 ± 3.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6 ± 5.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.40 (‐2.98 to 0.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (4 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.5 ± 21.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.5 ± 32.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.0 (‐16.89 to 2.89)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Enoximone versus dobutamine</b><br/> <br/> <br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (12 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56 ± 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.74 (‐0.75 to 0.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (14 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 ± 0.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 0.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.97 to 0.37) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (12 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 ± 5.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.7 ± 6.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.70 (‐9.11 to 1.71) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0010" title="LanconJP , CaillardB , VolotF , ObadiaJF , BockF . Comparison of enoximone versus tobutamine in the treatment of low cardiac output after cardiac surgery [Comparaison de l'enoximone et de la dobutamine dans le traitement du bas debit cardiaque apres chirurgie cardiaque]. Annales Francaises d'Anesthesie et de Animation1990;9(3):289-94. ">Lancon 1990</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (14 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 ± 4.2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8 ± 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (‐3.34 to 3.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (12 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.0 ± 11.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 ± 17.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.0 (‐27.55 to ‐2.45) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p> <b>Epinephrine versus norepinephrine</b><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (72 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (1.9 ‐ 3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (2.2 ‐ 3.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (72 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5 ± 4.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8 ± 5.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.30 (‐5.86 to ‐0.74) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (72 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.7 ± 12.3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.5 ± 8.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.20 (1.73 to 12.67) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Dopamine‐milrinone versus dopamine‐dobutamine</b><br/> <br/> <br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (1 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 ± 0.31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 ± 0.63 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.74 to 0.14) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (1 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.0 ± 4.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.0 ± 6.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.0 (‐6.78 to 2.78) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0015" title="MeissnerA , SchmelzleT , SimonR . Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine [Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin]. Zeitschrift fur Kardiologie1996;85(11):839-46. ">Meissner 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (1 h after treatment initiation; mmHg)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.0 ± 7.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.0 ± 12.01 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0 (‐14.91 to 2.91) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Enoximone versus piroximone</b><br/> <br/> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac index (3 h after treatment initiation; L/min/m<sup>2</sup>)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 ± 0.5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 ± 0.4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.10 (‐0.50 to 0.30) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCWP (3 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 ± 2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.70 (‐2.41 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP (3 h after treatment initiation; mmHg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.9 ± 8.7 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.6 ± 7.0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.30 (‐3.62 to 10.22)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval<br/>IQR: interquartile range<br/>MAP: mean arterial pressure<br/>MD: mean difference<br/>PCWP: pulmonary capillary wedge pressure<br/>SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Haemodynamics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009669-tbl-0013"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Primary studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> (no MACE) </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> </tr> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>total</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="48" valign=""> <p><b>Levosimendan versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute kidney failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (7.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> <p>(30.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (2.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angina pectoris</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>680</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>, <a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 (8.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>848</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(Congestive) cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 (16.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134 (20.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (4.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disorder aggravated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1,9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (4.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (2.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>728</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (7.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (9.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111 (14.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (12.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (5.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (4.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0008" title="García-GonzálezMJ , Dominguez-RodríguezA , Ferrer-HitaJJ , Abreu-GonzálezP , MuňozMB . Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. European Journal of Heart Failure2006;8:723-8. [DOI: 10.1016/j.ejheart.2006.01.007]Samini-FardS , García-GonzálezMJ , Domínguez-RodríguezA , Abreu-GonzálezP . Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International Journal of Cardiology2008;127:284-7. [DOI: 10.1016/j.ijcard.2007.04.143]">Garcίa‐González 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple organ failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle spasms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (6.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49 (7.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (11.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain in extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (1.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>728</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolonged ventilatory assistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (8.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (32.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (3.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (2.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (13.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic inflammatory response syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (5.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (22.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (11.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (11.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (3.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (4.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vasoplegia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (13.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0002" title="AlvarezJ , BouzadaM , FernandezAL , CaruezoV , TaboadaM , RodriguezJ , et al. Hemodynamic effects of levosimendan in patients with low cardiac output after cardiac surgery. Revista Espanola de Cardiologia2006;59(4):338-45. ">Alvarez 2006</a>, <a href="./references#CD009669-bbs2-0011" title="LevinRL , DegrangeMA , PorcileR , SalvagioF , BlancoN , BotbolAL , et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome [Superioridad del sensibilizante al calcio levosimendan comparado con dobutamina en el sindrome de bajo gasto cardiaco postoperatorio]. Revista Espaňola de Cardiología2008;61(5):471-9. ">Levin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (13.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular extrasystoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0005" title="FollathF , ClelandJG , JustH , PappJG , ScholzH , PeuhkurinenK , et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196-202. ">Follath (LIDO) 2002</a>, <a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>760</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0014" title="MebazaaA , NieminenMS , PackerM , Cohen-SolalA , KleberFX , PocockSJ , et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA2007;297(17):1883-91. ">Mebazaa (SURVIVE) 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Levosimendan versus placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (25.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009669-bbs2-0009" title="HusebyeT , EritslandJ , MullerC , SandvikL , ArnesenH , SeljeflotI , et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European Journal of Heart Failure2013;15(5):565-72. [DOI: 10.1093/eurjhf/hfs215]">Husebye 2013</a>, <a href="./references#CD009669-bbs2-0018" title="SlawskyMT , ColucciWS , GottliebSS , GreenbergBH , HaeussleinE , HareJ , et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation2000;102(18):2222-7. ">Slawsky 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Levosimendan versus enoximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD009669-bbs2-0006" title="FuhrmannJT , SchmeisserA , SchulzeMR , WunderlichC , SchoenSP , RauwolfT , et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical Care Medicine2008;36(8):2257-66. [DOI: 10.1097/CCM.0b013e3181809846]">Fuhrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute renal failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (31.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (56.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need of mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (81.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (93.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (43.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (18.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic inflammatory response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (81.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular tachycardia or fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (50.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (68.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Epinephrine versus norepinephrine‐dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0012" title="LevyB , PerezP , PernyJ , ThivilierC , GerardA . Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Critical Care Medicine2011;39(3):450-5. [DOI: 10.1097/CCM.0b013e3181ffe0eb]">Levy 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supraventricular arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sustained ventricular tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (6.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><b>Dopexamine versus dopamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD009669-bbs2-0017" title="RosseelPM , SantmanFW , BouterH , DottCS . Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?Intensive Care Medicine1997;23:962-8. ">Rosseel 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal blood loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (11.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (8.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Junctional rhythm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kidney failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (2.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premature atrial contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (17.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Premature ventricular contractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (25.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (31.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><b>Milrinone versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009669-bbs2-0004" title="FeneckRO , SherryKM , WithingtonPS , Oduro-DominahA , European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2001;15(3):306-15. ">Feneck 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atrial fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (18.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (15.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (5.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (13.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (40.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oligouria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (8.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (18.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Enoximone versus dobutamine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD009669-bbs2-0003" title="AtallahG , GeorgeM , LehotJJ , BastienO , BejuitR , DurandPG , et al. Arrhythmia in patients with low cardiac output after valvular surgery. Randomized, double-blind comparative study of dobutamine versus enoximone [Arythmies chez les patients en bas debit cardiaque apres chirugie valvulaire]. Archives des Maladies du Coeur et des Vaisseaux1990;83(3):63-8. GeorgeM , AtallahG , LehotJJ , BastienO , DurandPG , EstanoveS . Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(Spec 3):57-62. ">Atallah 1990</a>; <a href="./references#CD009669-bbs2-0007" title="GalinierM , RochiccioliJP , EdouardP , FourcadeJ , MassabuauP , PuelJ , et al. A comparison of enoxime and dobutamine in severe chronic congestive cardiac failure with low cardiac output. Antagonistes de L'angiotensine II: une Voie Prometteuse1990;83(SPEC 3):27-32. ">Galinier 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (5.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatic cytolysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia and/or hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (21.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular hyperexcitability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Epinephrine versus norepinephrine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009669-bbs2-0013" title="LevyB , Clere-JehlR , LegrasA , Morichau-BeauchantT , LeoneM , FrederiqueG , et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. Journal of the American College of Cardiology2018;72(2):173-82. LevyB , MezianiF , LeoneM , GuiotP , QuenotJP , LouisG ,  et al. CO-65 Comparison of epinephrine and norepinephrine for the treatment of cardiogenic shock following acute myocardial infarction. OPTIMA CC study. Annals of Intensive Care2018;8(Suppl 1):13. ">Levy 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (40.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for extracorporeal life support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (11.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Refactory shock</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (37.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (6.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Enoximone versus piroximone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0016" title="PatelA , CaldicottLD , SkoylesJR , DasP , SherryKM . Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. British Journal of Anaesthesia1993;71(6):869-72. ">Patel 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (10.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Enoximone versus epinephrine/nitroglycerine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009669-bbs2-0019" title="ZwolferW , DresslerHT , KeznicklP , DieterichHA . Enoximone versus epinephrine/nitroglycerin in cardiac low-output states following valve replacement. Clinical Cardiology1995;18(3):145-9. ">Zwölfer 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arrhytmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>LIDO: study title ("levosimendan infusion versus dobutamine")<br/>MACE: major adverse cardiac events<br/>MAP: mean arterial pressure<br/>ST: segment of the electrocardiogram<br/>SURVIVE: study title ("survival of patients with acute heart failure in need of intravenous inotropic support") </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/full#CD009669-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Levosimendan versus dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause long‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause long‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 MACE (Perioperative infarction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 MACE (Cerebrovascular accidents) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.14, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.14 [‐6.23, ‐2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.15 [‐4.61, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Levosimendan versus dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levosimendan versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause long‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.16, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause long‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.15, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.14, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.50 [‐8.44, ‐2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levosimendan versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Levosimendan versus enoximone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 MACE (Cerebrovascular accidents) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Levosimendan versus enoximone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Epinephrine versus norepinephrine‐dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Epinephrine versus norepinephrine‐dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopexamine versus dopamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 MACE (Perioperative infarctions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Hemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopexamine versus dopamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Milrinone versus dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Milrinone versus dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Enoximone versus dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.64, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐4.97, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Enoximone versus dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Epinephrine versus norepinephrine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 All‐cause long‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 All‐cause long‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Epinephrine versus norepinephrine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Dopamine‐milrinone versus dopamine‐dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 All‐cause short‐term mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 All‐cause short‐term mortality: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Dopamine‐milrinone versus dopamine‐dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009669-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Enoximone versus piroximone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Haemodynamics (Cardiac index) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Haemodynamics (Pulmonary capillary wedge pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Haemodynamics (Mean arterial pressure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Enoximone versus piroximone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009669.pub4/references#CD009669-tbl-0023">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009669.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009669-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009669-note-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009669-note-0023">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009669-note-0021">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD009669-note-0019">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009669-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD009669-note-0017">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD009669-note-0016">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD009669-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009669-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009669-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009669\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009669\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009669\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009669\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009669\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009669.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009669.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009669.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009669.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009669.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718904710"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009669.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718904714"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009669.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddbb93f861be5',t:'MTc0MDcxODkwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 